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001 CAN THE PRESENCE OFMICROMETASTASES
(MM) IN PRIMARY BREAST CANCER (PBC)
PREDICT OUTCOME? LONG TERM (MEDIAN 12.5YRS)
FOLLOW UP. H Gogas', JL Mansi', J Bliss2, and RC Coombes3.
'Dept Oncology, St George's Hosp, London SW17 OQT, 2lnstitute of
Cancer Research, Surrey, SM2 5NG, 3Charing Cross Hospital,
W6 8RF
Bone marrow (BM) MM were first identified immunocytochemically
in patients with PBC in 1981. We report the longterm follow up of
350 PBCpatients (median age 59 years; range 26 to 85 years) who had
multiple aspirates taken between 1981 and 1986 at the time of initial
surgery . The BM was examined with anti-EMA. MM were found
in 89 (25%) patients. Their presence was related to various poor
prognostic factors: pathological size (PS), peritumoral vascular
invasion (VI) and +ve lymph nodes (LN). At a median follow up of
12.5 years 151 patients have metastatic disease, the 10 year relapse-
free survival is 43.9% (CI 33.4-54.7%) in patients with MM and
62.7% (CI 56.5-68.6%) in patients without MM at presentation
(logrank test 12.23; df = 1; p < 0.001). Cox regressionanalysis for
relapse-free survival after allowing for PS, LN and VI shows that the
effect of MM is reduced and no longer significant. 179 patients have
died, 136 from breast cancer. The 10 year survival is 44.9% (CI
34.2-55.9%) for patients with MM and 65.7% (CI 59.4-71.5%)
without (logrank test 13.90; df = 1; p < 0.001). Again Cox
regression analysis for overall survival, after allowing for other
prognostic factors, shows that MM as anindependent factor is reduced
and no longer significant. Therefore even though the shorter disease-
free and overall survival occurs in patients with MM it is not an
independent prognostic factor. Thus this technique may be of more
value where PS, VI and LN status are unavailable such as in patients
receiving primary medical therapy.
003 LOCAL RECURRENCE OF BREAST CANCER: NEW
CONCEPTS ABOUT ITS BIOLOGY AND CLINICAL
RELEVANCE. J S Vaidya*1, I Mittra2, M Baum', 'Departments of Surgery at University College London, 67-73 Riding House Street,
London, WI P 7LD,UK, and at 2Tata Memorial Hospital, Bombay, 400 012, India.
It is believed that breast cancer is multicentric and harbours microscopic
foci of cancer apart from the presenting tumour. A detailed pathological analysis by
Holland et al (Cancer,1985;56:979-90) suggested that although multicentric foci
(MCF) are present all over the breast, 90% of them are found in the index quadrant.
In randomised clinical trials of breast conservative therapy it was found that
radiotherapy effectively reduced the incidence of local recurrence. Additionaly, in
these trials, >90% of eariy breast recurrences were found to occur in the index
quadrant and therefore it was believed that they arise from MCF and that all MCF
correctly deserved treatment with whole breast radiotherapy.
However, results of our recent analysis of spatial distribution of MCFwithin
the breast suggest a different picture. We used the relative positions within the breast
of the primary tumour and MCF were used to calculate the relative distribution of
primary tumour and MCF in the 4 quadrants of the breast and the percent breast
volume that would be required to be excised to include all MCF. The relative
distribution of primary tumour and MCF in the 4 breast quadrants was significantly
different (p=0.034). MCF were present beyond the index quadrant (25% of breast
volume including the tumour) in as many as 79% (15/19) of breasts that harboured
MCF; and, in half the cases (15/30) when all breasts were considered. Thus, in half
of all patients, MCF are present in other quadrants. If MCF were giving rise to the
early breast recurrence half would have occurred in other quadrants; but 90% of
early breast recurrence occurs in the index quadrant, whether or not radiotherapy is
given. We also know that local recurrence occurs in the index quadrant irrespective
of clear margins, which suggests that it does not arise from overlooked tumour.
Interestingly, a recent paper (Deng G et al, Science,1996;274:2057-59) has
demonstrated a loss of heterozygocity in morphologically normal tissue at the
excision margins of breast cancer.
We propose that local recurrence arises a) from circulating metastatic
cancer cells lodging in the highly vascular surgical bed (local relapse does harbinger
a poorer prognosis) or b) from local trasfection of surrounding breast epithelium by
nuclear material released from the original malignant clone resulting in insertional
mutagenesis. Thus although the margins of excision are morphologically clear, they
may be genetically unstable.
In any case, if MCF do not give rise to breast recurrence then why should
we treat them with either mastectomy or whole breast radiotherapy? It is as
necessary or as unnecessary as treating the contralateral breast! We have begun
pilot studies of a clinical trial to test whether radiotherapy to the index quadrant alone
can achieve good local control.
002 A COMPARISON OF ISOCENTRIC AND CONVEN- TIONAL PLANNING IN INTACr BREAST RADIO-
THERAPY. S.Pledge',C.AnthonyG.Brown'
S.Young2,J.Conway,2M.Robinsonl,'YCRC Acad.Dept.Clin.Oncology
2Physics Dept., Weston ParkHospital, Whitham Road, Sheffield UK.
Introduction The accuracy of breast radiotherapy has now
become an important clinical and legal issue. To improve accuracy we
have recently developed an isocentric technique which requires
simulator time notneeded with ourconventional technique.
Aim To compare the volume of lung irradiated, the day to day
accuracy and the costs ofeachtechnique.
Patients 57 isocentric plans (IP) and 40 non isocentric plans
(NIP) patients were studied. A subset of 32 of each had the Central
LungDistance (CLD) determined
Methods Portal images of treatment fields have been acquired
using Portal Vision or film, mean 9.8 images per IP and 8.3 for the
NIP. The CLD was determined as the distance from the posterior field
edge to the anterior chest wall on the beam axis. A more detailed
analysis was also employed, using the Portal Image Processing System
2 (PIPS2, Manitoba Cancer Treatment and Research Centre) This
computerises the registration of the reference and treatment portal
images. The breast outline is marked on a digital image, and
registration performed using a least square fit of the curves. Any
resultant translation of the field centre is recorded as X and Y values
with an assessment ofaxial beam rotation.
Results The mean CLD on the first portal image for the NIP was
21.9 mm (1SD 5.6), and on the simulated CLD for the IP was 18.4
mm (1SD 9.7). The numbers of images where the CLD exceeded 30
mm was 3 for the IP and 10 for the NIP (X2 5.11, p 0.02). There was
no significant difference in variability of rotation or longitudinal
accuracy between the techniques. The mean variation in lung radiation
was significantly greater in the NIP (2.33mm (95%CI 1.94-2.72) vs
0.92mm (95% CI 0.42-1.42)
Conclusions Use of the isocentric technique reduces lung
irradiation and set up inaccuracy whilst inter fraction variation is
unchanged. This is achieved at the cost of increased radiographer and
PhysicsDepartment input.
004 ROLE OF RADIOTHERAPY IN EARLY BREAST
CANCER (STAGE 1). A WEST MIDLANDS BREAST
GROUP PROSPECTIVE RANDOMISED COLLABORATIVE STUDY
(BR3002). D.Spooner,J.M.Morrison,G.D.Oates,D.J.EIlis,M.J.R.Lee,
A.Aukland,R.J.Grieve,R.J.Blunt,H.M.Bishop,J.A.Dunn,C.Jevons,
K.Milligan,L.Dodson. CRC Trials Unit on behalf of the West Midlands
Breast Group, Queen Elizabeth Hospital, Birmingham, U.K, B15 2TA
Between August 1985 and December 1992, 707 patients
with early breast cancer (less than 4cm diameter with clinically
negative axillae) were treated with wide local excision only and
then randomised to receive immediate post-operative radiotherapy
to the breast and axilla or observation only. All patients received
adjuvant Tamoxifen for a minimum of two years.
After a median follow up of 7 years, 530 patients are still
alive and 37 have died from conditions unrelated to carcinoma of
the breast. The overall two year actuarial survival is 93%. There is
no significant difference between those receiving radiotherapy
(93%) and those who were subsequently observed (92%)
(x2=1.81, P=0.18).
There is a difference in the two year actuarial relapse rate:
8% in those who received radiotherapy and 18% in those who did
not (overall 13%). This is statistically significant (X2=24.1,
P<0.0001). There was no difference in the two year distant
metastatic relapse rate: 11/343 in the no-radiotherapy group,
16/348 in those who received radiotherapy (X2=0.89, P=0.34).
However, there was a very significant difference in locoregional
relapse at two years: 51/343 in those who did not receive
radiotherapy, compared with 16/348 in those who did (X2=20.8,
P<0.000I).
This trial was supported by the Cancer Research Campaign.18 Oral Presentations
005 LOCAL IRRADIATION REDUCES BREAST
RELAPSESIN PRESENCE OF SYSTEMIC
ADJUVANT THERAPY. I Potyka, M Fennessy, J Houghton, M Baum,
W Odling-Smee on behalfofthe CRC Breast Cancer Trials Group
In view of the increased use both of local excision as initial surgery and
of adjuvant systemic therapy a multi-centre randomised controlled trial
was designed to evaluate whether women with early operable breast
cancer, for whom adjuvant systemic therapy was planned, required
radiotherapy to prevent local relapse. Following primary surgery patients
were randomised, with consent, to either the radiotherapy arm or to the
control arm, using uncertainty as the criteria. Radiotherapy was given
according to local protocols. Depending on age, patients were also
entered into the CRC Adjuvant Breast Trial for Patients under the Age of
Fifty (a 2x2 factorial design evaluating Zoladex and tamoxifen for 2
years) or into the CRC Adjuvant Breast Trial for Patients over the Age of
Fifty (in which patients were randomised after completing two years of
tamoxifen to continue for afurther three years or to stop).
Between the launch in 1986 and 1995 when the trial was closed 585
patients were randomised by 35 clinicians in the UK. This analysis
included 535 eligible patients who had been followed for at least one
year: 265 patients received radiotherapy and 270 were randomised into
the watch policy group.
At a median follow-up of 3.4 years (range 0.2-8.4 years; live patients) a
significant reduction in local recurrence in the radiotherapy arm was
demonstrated (RR = 0.36; 95% CI 0.23 0.57). There was no difference
in overall survival between the two groups (RR = 1.2; 95% CI 0.8 - 1.8:
logrank analysis). The number of uncontrolled local recurrences at death
was the same in the two arms.
For patients receiving systemic adjuvant therapy for early breast cancer
the reduction in risk of local relapse from 36% at five years to 14% by
radiotherapy may justify its use.
007
MITOZANTRONE AND METHOTREXATE
CHEMOTHERAPY WITH AND WITHOUT MITOMYCIN C
IN THE REGIONAL TREATMENT OF LOCALLY
ADVANCED BREAST CANCER. J.C.Doughty, E. Kane, T.G. Cooke, *C.S.
McArdle. University Departments of Surgery, Glasgow Royal Infirmary and
*Edinburgh Western General Infirmary, UK
Regional chemotherapy is one method oftreating patients with
locally advanced breast cancer. Conventionally it is delivered by
surgical implantation of a catheter into the subclavian artery but the less
invasive angiographic technique is increasingly being used.
There have been many reports of mitozantrone, methotrexate
and mitomycin (MIMM) administered regionally but we have
experienced severe wound breakdown associated with the use of
mitomycin C (MIMC).
This paper therefore compares the results and toxicity obtained
delivering mitozantrone and methotrexate (MM) with and without
MMC via angiographically placed catheters in the internal mammary
and lateral thoracic arteries.
Fifty-two patients with a histological diagnosis of locally
advanced breast cancer were recruited. Thirty-three patients received
MMM and 17 MM. The response rates as defined by WHO criteria
were as follows:
MMM MM
Number ofpatients 33 17
Complete response 11 5
Partial response 13 8
Stable disease 8 4
Progressive disease 1 0
There was no significant differences (X2 test p>0.7) between the
responders and non-responders in the two group, however local toxicity
was significantly increased in the patients who received MMM.
We conclude that regional chemotherapy using MM is as
effective as MMM in the treatment oflocally advanced breast cancer
and avoids the severe local skin reactions associated with MMM.
006 TIHE EFFECT OF NEOADJUVANT CHEMOENDOCRINE
THERAPY ON ANGIOGENESIS IN PRIMARY BREAST
CARCINOMAS. Makris A', Powles TJ', Kakolyris S2,
Ashley SE', Dowsett Ml' Harris AL2 'The Royal Marsden Hospital, Sutton
and London; 2ICRF Clinical Oncology Unit, Oxford, UK.
Survival in breast cancer patients is strongly predicted by the intensity of
angiogenesis, asmeasured bymicrovessel density (1). The impact of
chemotherapy and/or endocrine therapy on angiogenesis is unknown.
Histological samples were obtained from patients randomised to a trial of
neoadjuvant (NEO) vs adjuvant (ADJ) chemoendocrine therapy in operable
breast cancer. Patients received 4 cycles of chemoendocrine therapy prior to
surgerv in the NEO group. Chemoendocrine therapy consisted of
mitoxantrone 1 1mg/in2 and methotrexate 35mg/in combined with
tamoxifen 20mg/day (2MT). The two groups wvere comparable for age,
menopausal status, stage andsurgical requirements. From a random sample
of 216 patients (105 NEO and 111 ADJ) entered into the trial, invasive
cancer was identifiedin 195 patients (91 NEO anld 104 ADJ). Using these
samples immunostaining was performed vith the CD34 monoclonal
antibody and scoring ofmicrovessels done using the Chalkleymetlhod. The
median score oC NEO patients was 5.7 (95% CI 5.3 to 6.0) and for ADJ
patients was 6.3 (95% CI 6 to 6.7), p=0.025. Using previously validated
scoring categories (1) there were more good prognosis (score <5) samples
in the NEO group (30%) than in the ADJ group (19%) and correspondingly
less poor prognosis (score >7) samples in the NEO group (23%) than in the
ADJ group (34%) (p=0.04). These results suggest that neoadjuvant
chemoendocrinc therapy catuses a redLuction in microvessel density in
primary breast carcinomas. This effect could be either due to a direct effect
on angiogenesis or secondary to tunior regression.
1. Fox SB et al Quantitation and prognostic value of breast cancer
angiogenesis: comparison of microvessel density, Chalkey count, and
computer image analysis. J Path 1995, 177: 275-283.
008 A RANDOMSED PHASE I TRIAL OFINFUSIONAL 5-FU
AND EPIRUBICINWM1T CYCLOPHOSPHAMIDE V. CISPLATIN
IN ADVANCED BREAST CANCER. T.Eisen, I.E.Smith, P.A.Ellis, M.O'Brien,
J.Prendiville, A.Saini and S.Johnston. Royal Marsden Hospital, London SW3 6JJ.
Object of Study We previously developed an in-patient regimen
consisting of infusional 5-FU, epirubicin and cisplatin (ECisF) and a
response rate of 86% in metastatic/locally advanced breast cancer.
This phase II 2:1 randomised study investigates whether
cyclophosphamide (ECycloF) can be substituted for cisplatin to reduce
toxicity and allow the regimen to be administered on an out-patient
basis without loss ofefficacy.
Methods 76 women (30-73y, median 48y) with breast cancer (34
locally advanced, 42 metastatic) received continuous infusional 5-FU
(200mg/m2/day viaHickman line) and 6 cycles of epirubicin (60mg/m2
q2ldays) with either cyclophosphamide 600mg/m2 q2ldays (24 locally
advanced, 29 metastatic) or cisplatin 60mg/m2 q21days (10 locally
advanced, 13 metastatic). There were no significant differences in
patient characteristics between these groups.
Results There were no significant differences in toxicity between
ECycloF and ECisF; including WHO Grade 3/4 nausea and vomiting
(4% v 13%), gastrointestinal toxicity (11% v 13%), anaemia (0% v
4%), thrombocytopenia (2% v 4%) or leukopenia (22% v 14%).
Efficacy was comparable with overall response 68% v 65%, CR 15% v
17% and median progression-free survival 9 v 8 months.
Conclusion ECycloF is an out-patient regimen with no increased
toxicity over ECisF and with comparable efficacy.OralPresentations 19
009 SHOULD IMMEDIATE BREAST
RECONSTRUCTION BE AVAILABLE
TO ALL WOMEN UNDERGOING
MASTECTOMY?
R.AM. AM- Mufti, MG Berry, S Denton, M Sullivan, A Vaus, R Carpenter.
The Breast Unit, Royal Hospital's Trut at St. Bartholomew's Hospital, London
EClA 7BE
In the wilted kingdom, immediate breast reconstruction follownng
mastectomy for breast cancer has been available only to the few. The modem
Breast Surgeon has acquired reconstructive skills such that more women can
be offered immeiae restoration of body image with primary reconstruction,
but do the resuksjustify such intervention?
We present our experience and clinical outcomes of the first 100
patieits undergoing surgery in four years since the introduction of i ediate
breast reconstruction using the Becker tissue expansion prosthesis. As part of
the evaluation a retrosptive study was carried out by seding a detailed
questionnaire to all patients for subject ofassessment.
The median age was 52 years (range ofwomen undergoing imme
reconstruction was 25-74), 49 had stage I, 38 stage II and 13 stage HI disease.
Thirty-nine women received radiotherapy and twenty-six adjuvant
chemotherapy in addition to undergomg surgery. The clinical infction rate
was 140/o, however, organisms were grown in only 7%. Revisio surgery for
capsule contraction was undertaken in 28% with no statistical retionship to
either radiotherapy or chemotherapy (p value > 0.5). Eight womn have died
of breast cancer and of the group rmaiming that are alive, 87% express
satisfaction with the final aesthetic resu}e.
We conclude that immediate breast reconstruction may be offered to
more women undergoing mastecmy using the relatively simple technique and
without affecting adjuvant treatments. A high degree of patifet satisfaction
seems not to have been affected by the relatively high revision surgery rate of
28%.
011 EFFECTIVE TARGETING OF COLO-
RECTAL CANCER KIRS TEN RAS
POINT MUTATIONS WITH
ANTISENSE THERAPY IN-VITRO.
P.J. Ross, H.J.N. Andreyev,
D. Cunningham, P.A. Clarke
Unit, Royal
Marsden Hospital
& CRC Centre of Cancer
Therapeutics, Cancer Research, Sutton,Surrey
mutation of the Kirsten ras (Ki-ras) gene are
present of patients with colorectal cancer. Their presence is
outcome but they do offer an unique target for
therapies as antisense. It is known that replacement of
wildtype
Ki-ras in cell culture, reduces the cell's malignant
study
aimed to reverse the effect of a glycine to valine Ki-
mutation with antisense oligonucleotide therapy. Of all
possible mutations, this one
carries the worst prognosis.
Seven different, 17 nucleotide, phosphodiester backbone,
phosphorothioate capped antisense molecules were examined. A cell free
system
used to test each oligonucleotide's efficacy at inducing RNase
cleavage mutated mRNA. Wild type and codon 13 mutated
controls. These same oligonucleotides were also
against colorectal carcinoma cell lines in culture: SW480 with
target mutation, HT29 with wildtype Ki-ras and LoVo with a codon 13
permeabilised with streptolysin 0 and treated with 10
FtM
of each oligonucleotide. Thymidine incorporation into DNA measured
single
dose of each design on cellular DNA synthesis.
Protein expression
was examined by Western blotting. Each
oligonucleotide tested at least 12 times against each cell line. Every
experiment
included permeabilised control cells which were not treated
with antisense oligonucleotide.
thymidine incorporation after a single dose of
oligonucleotide varied from 5-32% in treated SW480 target cells but was
minimal control cell lines. Cleavage of mRNA seen in
system correlated with results obtained with cells in culture. In
cases, antisense molecules could cleave both target and control
mRNA. However, most effective molecule in the cell line assay
specifically
cleaved the target mRNA but not control mRNA.
Antisense oligonucleotides targeting point mutations in Ki-
mRNA have selective activity. This has been demonstrated in a cell
system and in cell culture. Efficacy of individual oligonucleotide
designs predicted empirically, but the most effective inhibition
culture appears
to occur because of selective RNase H
cleavage.
010 THYMIDINE SALVAGE DEMONSTRATED IN VIVO: A SPECIFIC
PHARMACODYNAMIC ENDPOINT OF THYMIDYLATE SYNTHASE (TS) INHIBITION.
P.Wells*l, R.N.Gunnl, A.Hughes2,G.A.Taylor2,P.Pricel,D.R.Newell2.
1. MRC CU, Hammersmith Hospital, London W12 OHS, 2. CRU,
Medical School, University ofNewcastle, Newcastle NE2 4HH.
Object of study: THYMITAQTM is a nonclassical TS inhibitor. We
aimed to assess whetheractivity ofthymidinesalvagepathways could
be demonstrated in tissues following treatment. This may then be used
as a specific in vivo pharmacodynamic endpoint of TS inhibition.
Methods: Five patients in the Cancer Research Campaign (CRC)
Phase I trial ofTHYMITAQTm and three controls were studied. Paired
[2-1lCIthymidine PET scans wereperformed, onebefore treatment and
one on the second day of therapy, one hour after oral administration
of THYMITAQTM (250mg/M2). PET tomographic data was acquired
over 60 minutes with continuous arterial blood sampling measures
allowing the calculation of a plasma thymidine input function (IF).
Spectral analysis was used to deconvolve the IF from the PET data to
give a unit impulse response function (IRF) for each tissue region.
Measurements oftracerdelivery (IRFimin), and retention(IRFlho,,0)were
obtained. The %difference in IRFlhour between each pair of scans is
used as anexpression ofchange ofthymidineretention.
Results: No change was seen in extraction of tracer from the blood
and delivery to the tissues as a result of the drug administration.
There was a statistically significant increase in the retention oflabelled
thymidine at the end of the study relative to controls in the tumour
regions (THYMITAQTm mean +40% range +10% - +75%, controls
mean -11% range +4% - -24% p<O.O1 paired ttest). No change in the
normal tissue (liver) was found.
Conclusion:Thymidine kinase and other salvage enzymes are active
following TS inhibition to restore intracellular levels of thymidine
nucleotides. The increase in tissue [2- 11C]thymidine concentration
after administration of THYMITAQTM is consistent with enhancement
of the thymidinesalvagepathway in tumourrelative to normal tissue.
SupportedbyCRCGrantNoSP2193/01,2 & Agouronpharmaceuticals.
012 IDENTIFICATION OF CIRCULATING TUMOUR CELLS BYRT-
PCR IN PATIENTS W1THCOLORECTAL CANCER; DETECTION
PRIOR TO EVIDENCE OF METASTASIS. SK Jonias, A Klokotuzas,
RQ Whartoii & TGAllen-Mersl, Dept. ofStirgery Chelsea & WestiniisterHospital,
CXWMS, Londoni SW1O 9NH
Carcinoembryonic antigen (CEA), a member of the immunoglobulin
superfamily is an epithelial specific antigen. Identification of CEA
RNA in the circulation therefore precludes the transcription ofCEA by
haemopoietic cells.
We have previously identified CEA cDNA by RT-PCR in patients with
colorectal liver metastasis (LM). Sensitive detection was achieved by
Southernblot hybridisation using an oligoprobe which lies between the
CEA specific primers used and identity of PCR products was
confirmed by sequence analysis. Extracted RNA from granulocytes
which express non-specific cross-reacting antigen (NCA), a closely
related member of the CEA family and with substantial sequence
homology, was amplified by NCA-specific primers but not by CEA
primers, eliminating the possibility of granulocyte contamination. Our
studies now demonstrate that the prevalence of CEA RNA expression
in blood sampled preoperatively is similar in patients with primary (PR)
colorectal cancer without evidence of metastasis as confirmed by CT-
scan (PR, no LM 11/20, 55%; PR with LM 36/54, 67%). The
application of a cannula for venous sampling to prevent skin cell
contamination established that 23 non cancer control patients were
negative on Southern blot hybridisation.
Multiple sampling in which 2 samples were taken within one circulation
time and a further sample outside this time resulted in increased
frequency ofdetection. CEA cDNA amplification occurred in 61% of
colorectal cancer patients from only a single sample of blood, but
increased to 94% overall positive expression (15/16 patients, 7 PR
with and 8 without LM) when 3 separate samples were taken. This
suggests that multiple tumour cell clusters are present in the circulation
ofall these patients.
The identification of circulating CEA producingcells in patients
without evidence ofmetastasis may be ofclinical importance.20 Oral Presentations
013 INVESTIGATION OF THE ANTITUMOUR ACTION OF
COMBRETASTATIN A4 AND ITS PHOSPHATE
ANALOGUE. K. Grosios. A.T. McGownt. G.R.Pettit2.
M.C. Bibbv. Clinical Oncology Unit. University ofBradford. Bradford BD7
IDP. UK. PatcrsonInstitute for Canlcer Research, Manclhester M20 9BA,
UK. 2Arizona StateUniversitv. Tempe. Arizona 85287-1604. USA
Currently one of the main interests in cancer research is the
identification of clinicallv useful targets. Tumour vasculature
manipulation and interference with blood vessel formation
(angiogenesis) are providing such targets and related drugs are
increasingly considered for clinical trial, one of which is
Combretastatin A4 (C-A4). In this study, the possible mechanism(s) of
action of C-A4 and its phosphate analogue have been investigated in
clinically relevant in vivo and in vitro models. Intraperitoneal
administration ofC-A4 (150 mgkgt) and the phosphate analogue (100
mgkg- ) have resulted in complete vascular shutdown (as assessed by
Hoechst 33342 studies) and extensive haemorrhagic necrosis in
MAC15A subcutaneous and MAC15 orthotopic colon tumours in
mice.Orthotopic transplantation results in formation of metastatic
deposits. Small avascular deposits observed in the lungs of mice were
unaffected by both compounds, whereas areas of focal necrosis were
found in diaphragm, kidney and lymph node deposits, which do
develop a vascular supply. Human Umbilical Vein Endothelial Cells
(HUVEC) grown in type-I calf-skin collagen form tubular networks.
Exposure of such networks to 0.31 tNM (non-cytotoxic) concentration
ofboth C-A4 and its analogue results in disruption of such networks,
which begins after 4h and is completed by 24h. Similarly, the same
concentrations inhibit migration of HUVEC through collagen. Staining
for F-actin and immunofluorescence for tubulin have shown complete
disoruanisation and disruption of the cellular cytoskeleton after 4h
exposures. C-A4 and its phosphate analogue exhibit antitumour effects
which may result from a combination of antivascular and
antiangiogenic actions.
015 NVESTIGATIONS OF A CYCLIC PEPTIDE
ANTAGONIST OF THE aVP3 1N1TEGRIN:
IMPLICATIONS FOR TARGETED TUMOUR
THERAPY, R. Allman, W. G. Jiang*, P. Cowbum and M. Mason, Research
Department, Section of Clinical Oncology, Velindre Hospital, Cardiff CF4
7XL, *Department of Surgery, University ofWales College ofMedicine.
Results of systemic therapy for metastatic malignant melanoma,
including cytokine based therapies, are disappointing. Rational drug design
requires that a specific tumour-associated property is identified and an
appropriate drug identified or designed to specifically target that property.
Upregulation of the ccvp3 integrin (vitronectin receptor) is associated
with increasing metastatic potential in malignant melanoma.
We have investigated the activity of the cyclic pentapeptide cRGDfV
(which is a potent inhibitor of exvp3) on a panel of melanoma cells derived
from different stages of tumour progression. All ofthe cell lines express high
levels of sxvP3, with one ofthe cell lines also expressing low levels ofavP5.
Our studies indicate that cRGDfV (i) inhibits xvP3 mediated cell
adhesion with a IC50 value of 0.2,uM (ii) prevents colony formation in
3-dimensional collagen gels (iii) induces apoptosis of cells maintained in
3-dimensional collagen gels.
Preliminary investigations into the mechanism ofthe activity of cRGDfV
indicates that peptide binding induces a rapid (< 5 minutes) dismantling of
Focal Adhesion Complexes, phosphorylation of paxillin, and is associated
with a calcium transient. The potency of cRGDfV is further illustrated by the
ability ofthe peptide to induce apoptosis even in the presence ofhigh levels of
BCL2 and that exogenous peptide administered to cells already attached and
growing on type I collagen coated surfaces results in rapid rounding up and
detachment ofcells.
This observation indicates that the drug may not be relying upon contact
inhibition for its effects. Administration of cRGDfV to normal skin derived
fibroblasts, which express low levels of txvp3 and high levels ofaxv,5, caused
no detectable change in morphology or viability ofthe cells.
014 THE ENDOTHELIAL CYTOSKELETON AS A
TARGET FOR CANCERTHERAPY
GG Dark, SA Hill, DJ Chaplin. Tumour Microcirculation
Group, Gray Laboratory, Northwood, Middlesex HA6 2JR.
Many anticancer agents act on rapidly proliferating cells, without regard for the
malignant phenotype and a major pharmacological goal remains the development of
highly selective non-toxic therapies for the treatment of malignancies. Vasculature is
critical to both the survival of a solid tumour mass and its continued growth. Indeed
tumours cannot grow beyond 1-2 mm in diameter without developing a functional
blood supply. The tubulin and actin cytoskeleton are critical for the endothelial
process of; angiogenesis, cell division, motility, morphology, vascular permeability
and the intracellular transport ofmacromolecules and receptors to the cell membrane.
Using a tumour microenvironment model system we have examined the
cytotoxic effects of a number ofcytoskeletal agents. The tubulin polymerisation and
depolymerisation inhibitors show a preferential action against endothelium,
compared to cancer cells. Podophyllotoxin, although a weak tubulin-binding agent, is
more toxic to tumour cells than endothelium. Colchicine, Dolastatin, Taxotere,
Vinblastine, Vincristine and Combretastatin have increased toxicity towards
endothelium, with enhancement of this action under hypoxic(1% 02) conditions,
with furtherpotentiation for Taxotere and Vincristine in coculture with tumour cells.
Tumour cells show a reverse relationship with increased resistance to these agents
under hypoxia. Thecytotoxic action of these agents is greatest against proliferating
endothelium, and this mayexplain the enhancement seen with coculture as the breast
cancer cell lines studied produce VEGF in significant quantities. In contrast,
endothelium that is quiescent, prior to and during drug exposure, is significantly
more resistant to the actions oftheseagents, particularly combretastatin A-4 prodrug.
In view of these selective actions against endothelium, vascular studies were
performed in experimental and human breast cancer models in vivo. Histology of a
variety ofhuman xenografts and murine transplants indicated extensive haemorrhagic
necrosis with the cytoskeletal agents Colchicine, Vinblastine and Vincristine,
although only when administered at the maximum tolerated dose. Taxotere does not
share this effect. Following systemic administration ofcombretastatin A-4 prodrug at
100 mg-kg' (<10% MTD), extensive haemorrhagic necrosis was visualised at 6
hours in our breast cancer model system, with a selective and rapid reduction in
functional vascular volume of93%, persisting even after 18 hours.
These studies indicate that directing agents against the endothelial
cytoskeleton, can elicit selective effects against proliferating endothelial cells in
vitro, and induce rapid vascular shutdown within tumours in vivo, thus demonstrating
the clinical potential ofthis approach.
6 A RANDOMISED PHASE 2 STUDY OFBB-I0ol0 (MACROPHAGE 016 | INFLAMMATORY PROTEIN l-a) IN PATIENTS WITH ADVANCED BREAST
CANCER RECEIVING5-FU, ADRIAMYCIN AND CYCLOPHOSPHAMIDE (FAC)
CHEMOTHERAPY.
M.J. Clemons E Marshall',J. Durig K.Watanabe ,D. Miles',H Earl ,BI LordJ Kiernan',KTowlson2
.A Griffiths',P DeTakats3, T.M Dexter', N G Testa',A. Howell'. British Biotechplc, Oxford,U.K. KCRC
Dept. ofMedical Oncology and Paterson Institute forCancer Research, Christie Hospital, Manchester UK.
M204BX. ICRF Clinical OncologyUnit,Guy'sHospital, London,UK SEI 9RT,3CRC Institute ofCancer
Studies, Birmingham,UK B15 2TT.
Whilsthaematopoietic growth factors(HGFs) are established means ofrestoring neutrophil
counts following cytotoxic chemotherapy, the bone marrow stem cells remain in cycle and they
too are affected by thechemotherapy.The consequence ofwhich is progressive bone marrow
damage and thrombocytopenia. A novel approach would therefore be to keep stem cells out of
cycle during periods ofcytotoxic treatment to protect the quality ofthe normal stem cell
population and thereby maintain the bone marrow reserve. 13-l00l0 is a variant of the human
form ofMacrophage Inflammatory Protein I-ce and has been shown in mice to both block entry
ofhaematopoietic stem cells into S-phase and to increase the self-renewal capacity during
recovery from cytotoxic damage.Between August 1995 and March 1996, 30 patients with
locally advanced or metastatic breast cancer were entered into the first randomised, controlled
phase 2 study designed to evaluate the potential myeloprotective effects ofa seven day regimen
ofBB-10010 in patients receiving 6 cycles ofFAC chemotherapy ( 5FU 600mg/M2n, Adriamycin
50mg/miCyclophosphamide 600mg/M2n, every 3 weeks). BB-10010 was administered as a sc
in'jection once daily ondays 0-6 of each treatment cycle, the chemotherapy was administered as
abolus on day1. Patientcharacteristics; Median age 50 (29-64) years and median ECOG
performance status of 1 (0-2). All patients have now completed thestudy. 10 patients wvere
randomisedto100 .g/kgBB-IOOIO, II patients to 30lig/kgBB-100I0 and 9 control patients
received noBB-IOOIO BB3-10010 svas well tolerated in all patients with no severe adverse
events. 2 patients suffered repeated cutaneous reactionsat the injection sites. Bone Marrow
studies,to assess theLITBMC generation ofGM-CFC, were carried out immediately preceding
chemotherapy andat the endof'6cycles in 20patients. Neutrophils, platelets and circulating
progenitor cell levels (GM-CFC and CD34+ cells)were determined at serial time points in
cycles1,3&6. Preliminary analysis ofthe results show similarneutrophil and platelet kinetics in
all 3groups.Therc was anon-significant trend inneutrophil recovery in the treated groups 21
days aftercycle6. Neutrophil counts(xlO9)were; control group(1.7,SD+0.52), 30 pg/kgBB-
10010(2.14,SD+0.52), 100pig/kg BB-10010(2.67,SD+0.52). FAC chemotherapy was
associated with modest mobilisation ofprogenitor cellswith an attenuated response over
successive cycles ofchemotherapy. [he BM and peripheral blood progenitor level analyses will
be completed in Feb. 1997 and the final results will be presented.Oral Presentations 21
017 PHASE I STUDY OF THE BIODISTRIBUTION,
PHARMACOKINETICS & IMMUNOGENICITY
OF "'In-hCTMOl (CDP671) + PREDOSING WITH
UNLABELLED hCTMOl IN PATIENTS WITH LUNG CANCER.
G Middleton', M Verrill', K Priest', L Spencer', S Chittenden2, R
McCready2, N Cox3, L Skelton3, M O'Brien', I Smith'. 'Lung Unit;
2Plhysics Department, Royal Marsden Hospital, Downs Road, Sutton,
Surre*'. SM2 SPT, UK & 3Celltech Therapeutics Ltd. 216 Bath Road,
Sloh)glu, Berkshire, SLI 4EN, UK.
"'l'n-lhCTMOl is an enginieered hLumanl radiolabelled monoclonal
antibodly (Ab) to polymorphic epithelial miucin (PEM), a glycoprotein
over-expressed on the surface of SCLC & NSCLC cells. This study
was designed to confirmn previous safety data and to study
biodistribtution of "'lIn-hlCTMOl in patients (pts) with lung cancer. In
part I, pts received an IV inftusion of lmg/kg "'In-hCTMOL. In part
2, followinig a dose of 1 mg/kg unlabelled Ab (to saturate free PEM
bindinlg and redLuce liver Llptake of labelled Ab) pts received 0.1
mg/kg "'Iin-lhCTMOl. Toxicity was recorded using WHO criteria.
Plasimia levels of hCTMOl were measLured. Immunogenicity was
studied by measuLremnent of specific IgG and IgM titres.
BiodistribLution was measLured by whole body planar imaging. 21 pts
received Ab, 8 after predosing. Median age 66 (44-76); M 18, F 3;
SCLC 3, NSCLC 18. Infusions were well tolerated, 1 pt had a rigor
after "'In-hCTMOl. Mean t,12 was 44 hours.
BiodistribLutioll (% total close/organ) was:
liver kidney tulmour image seen
WithoLit pre-closinig 23.8 1.0 9/12 evaluable pts
With pre-dosinlo 17.7 1.8 4/7 evaluable pts
Pre-cosinlg with cold antibocly redluced liver uptake in the split dosing
I)art of the stLudy. In a forthcominig tlherapy stuLdy, hCTMOl will be
used conjuLgate(d with a cytotoxic drtug.
019 DOES THE HEREDITARY PROSTATE CANCER GENE,
HPC1 CONTRIBUTE TO A LARGE PROPORTION OF
FAMILIAL PROSTATE CANCER? - RESULTS FROM THE
CRC/BPG UK & CANADIAN CONSORTIUM.
R. Eelesl,2, J. Simard3, D. Teare4, S. Edwardsl, D. Easton4, D. Dearnaley2, F.
Durocher3, R. Shearer2, A. Ardern-Jones2, A. Dowe2, 105 collaborators5, S.
Narod6, W. Foulkes7.
Institute of Cancer Research1 and Royal Marsden Hospital2, Sutton; Institute
of Public Health, Cambridge4; The CRC/British Prostate Group Study
Collaborators5; UK and CHUL Research Centre, Quebec3; Cancer Genetics,
Toronto6 and Montreal General Hospitals7, CANADA.
There is evidence that prostate cancer has a genetic component; this is
demonstrated by the familial clustering of cases, the increased relative risk
of the disease in relatives of cases and the marked rise in this level of risk as
the clustering of cases increases in closeness of relationship or number of
affecteds. It has been estimated that up to 43% of cases at <55 years may be
due to a highly penetrant gene. Recently the first susceptibility prostate
cancer locus (HPC1) was mapped to chromosome 1q34 by linkage in a study of
91 families, most of which had 4 or more prostate cancer cases (Smith et al,
1996). However, most clusters in collections of familial prostate cancer
worldwide have 2-3 cases. The CRC UK familial prostate cancer study is the
largest collaborative UK effort to collect prostate cancer families, and has
105 collaborators via the British Prostate Group (BPG). A collaborative
Canadian effort has combined expertise and familial collections from 3
Canadian centres. Within this consortium, 140 families with > 2 cases of
prostate cancer have had blood DNA extracted. Only 15 clusters had > 4
cases. Four genetic lq markers, spanning the region within which HPC1 lies,
were run to assess linkage in these families. Overall, there is no significant
evidence of linkage to lq in these families; the total heterogeneity Lod score
was 0.12 with an expected 11% of families due to HPC1. This is lower than
the original 34% described. We therefore conclude that HPC1 contributes
more signficantly to larger prostate cancer clusters and that the majority of
smaller clusters of .3 cases are due to other gene(s).
This study is supported by the Cancer Research Campaign, UK and MRC of Canada.
(Smith et al 1996: Science. 274:1371).
018 VASCULARITY &THYMIDYLATE SYNTHASE LEVEL INFLUENCE COLORECTsAL LIVER METASTASES RESPONSE TO FLOXURIDINE.
MM Davies', D Burke', S Kaur', PG Johnston2, TG Allen-Mersh'.
'Department ofSurgery, Charing Cross & Westminster Medical School, Chelsea
& Westminster Hospital, London &2Department ofOncology, The Queen's University ofBelfast.
Drug delivery (tumour vascularity) and tumour resistance (thymidylate
synthase activity) may both be important in determining response to
regional infusion ofthe fluorinated pyrimidine floxuridine.
We have examined whether ofintratumoural thymidylate synthase and
vascularity correlate with response to FUDR, by staining liver metastasis
biopsies with anti-thymidylate synthase (TS106) and an anti-endothelial
(JC70) antibodies prior to intrahepatic FUDR treatment ofcolorectal
liver metastases.
Response was determined by comparing CT scans at the start and after
four months oftreatment. The intensity ofTS106 staining was assessed
by two "blinded" observers as either low (staining absent or weak) or
high (staining moderate or intense). Vascularity was assessed by a
graticule counting method at x200 magnification.
n
(patients)
Response No response p
TS106 High 12 3 9 0.049
(patients) Low 12 8 4
JC70 (Vessel Count 20 39.4 21.2 0.048
median,i.g.r.) (25.4-51.9) (12.5-34.8)
Vascularity was significantly (p=0.02) lower (median 15.2 i.q.r. 11.2-
22.0) in low TS staining tumours which did not respond compared with
those (median 39.4 i.q.r. 23.3-49.3) which responded.
Response by CLM to FUDR was associated with both lower TS levels
and higher tumour vascularity.
CLM Colorectal Liver Metastases FUDR Floxuridine
TS Thymidylate Synthase
020 DO BISPHOSPHONATES EFFECTTUMOUR BULK? CORRELATION OF TUMOUR MARKER, CLINICAL
AND BIOCHEMICAL EFFECTS. R. Colemanl, J. Vinholesl, 0.
Purohitl, A Milford-Ward2. YCRC Dept of Clinical Oncology, Weston
Park Hospital and Dept of Immunology, Northern General Hospital,
Sheffield.
Bone resorption results in the release of various cytokines and growth
factors which may provide an attractive environment for tumour growth.
Pamidronate is a potent inhibitor of bone resorption which reduces the
skeletal morbidity and bone pain associated with metastatic bone disease.
We have evaluated serum levels of the tumour markers CA15-3 and PSA
as surrogates for tumour bulk, and Ntx as a specific marker of bone
resorption in patients with breast (n=29) and prostate cancer (n=10)
respectively. Patients were randomised to receive intravenous
pamidronate 120 mg or a placebo infusion. Four weeks later all patients
received pamidronate 120 mg. Serum was collected every 4 weeks for
tumour markers and urine every 2 weeks for bone resorption markers
during the 12 week study period. During this time no systemic anticancer
treatments or radiotherapy were administered.
CA15-3 was elevated before treatment in 19 (66%) breast cancer patients
and PSA in 9 (90%) of prostate cancer patients. A >10% fall in tumour
markers was seen in 11 patients (39%) (8 breast and 3 prostate) after
pamidronate. This was only seen once (10%) with placebo. Changes
within the normal range were considered uninterpretable. 10 patients
(91%) with a >10% fall in tumour markers reported a >20%
improvement in pain score - derived from an amalgam ofpain intensity,
analgesic consumption and performance status - compared with only 3
(18%) who showed no change or a rise in markers (p=c1.Ol). Ntx fell to
normal (n=7) or was normal throughout treatment (n=3) in all the 10
clinical responders showing a fall in tumour markers of>10%
These data support the observations in animal models of a link between
bone resorption rates and tumour growth. The possibility that
bisphosphonates have an anticancer action as well as beneficial effects on
skeletal health deserves further study.22 Oral Presentations
021
TRANS-RECTAL ULTRASOUND GUIDED IODINE-125
IMPLANT FOR LOCALISED CANCER PROSTATE
AUTHORS: H. Al-Booz, D Ash, B. Carey, A. Flynn. Cookridge
Hospital, Leeds Object This work is done to determine the
acceptability and short-term side effects ofTRUS- guided I-125
implant for early cancer prostate. Methods 50 patients under the
age of 75, with clinically and radiologically confined carcinoma of
the prostate, and a prostate volume ofless than 50 cc were treated
at Cookridge Hospital, Leeds, with TRUS-guided iodine-125
Implant. Short-term side effects, urinary outflow score, bowel
dysfunction, potency, and quality oflife assessment (according to
the EORTC- QLQ-30) were assessed. Results After the first 12
patients who were hospitalised for 4 days, the remainder had a
mean stay of2.5 days.Two months post implant 35.5% of
patients had mild frequency ofmicturition, 27% moderate, non
severe, and no patients had incontinence. At six months15% of
patients still complained ofoccasional mild nocturia, hesitancy,
slight reduction in urinary stream, and none had incontinence.
No patients complained ofbowel symptoms. At six months 54%
of patients had retained potency, ofthese some had not yet
regained full potency after prior hormone therapy. Almost all
patients had a fall in PSA. At 2 months 53% had a PSA less than
4 ngm/ml. At six months 73% had a PSA less than 4. All patients
who work had returned to full-time employment within 3 weeks
ofimplantation. Conclusion Results show that the procedure
is completed within a minimum ofhospitalisation and with few
side effects. It is early to assess local control or late morbidity.
023 CARBOGEN OR HYPERBARIC OXYGEN FOR BLADDER
CANCER UPDATED PHASE11 RESULTS AND ANALYSIS OF
THE SECOND MRC HYPERBARIC OXYGEN TRIAL. Hoskin PJ, Saunders Ml, Verma N,
Powell MEB, Goodchild K, Dische S. MCRW, Mount Vemon Hospital,Northwood, Middx UK.
Atotal of 35 patients (mean age 68.5, 29 male) have been treated wfth radical
radiotherapy deliverng50-52.5Gy in 20 daily fractions to the bladder whilst
breathing carbogen (95% oxygen, 5%C02). Sixteen of these patients have in
addiftion taken oral nicotinamide 80mg/kg daily 2 hours pnor to radiotherapy. A
total of 26 patients are assessable by cystoscopy at least 6 months following
radiotherapy. Of these 24 (89%) have documented complete regression of
intravesical tumour. Three local relapses at subsequent check cystoscopy
have occurred these being seen at 10 months, 11 months and 30 months.
Acute morbidifty from treatment is no greater than expected wfthout carbogen
breathing and only one patient has significant late morbidifty wfth a fibrosed
shrunken bladder requiring catheterisation. There have been 9 deaths in this
series of 35 patients (primary bladder tumour 3, metastatic bladder cancer 3,
incidental death 3).
This series has been compared wfth an updated analysis of the second MRC
hyperbaric oxygen trial in bladder cancer. In this study 116 patients were
treated wifth radical radiotherapy delivering 48Gy in 14 fractions in air (56
patients) or 32Gy in 6 fractions in hyperbaric oxygen (60 patients). The
original findings of the MRC bladder trial are confirmed on 15 year follow-up
showing no dffference between the two arms of the trial for recurrence-free
interval or overall survival. Over 50% of bladder relapses in this trial were
seen in the first year after radiotherapy during which period the current Mount
Vemon carbogen series is demonstrating considerably better results, afthough
overall survival curves can be superimposed during this iniftial period. The
limitations of historical comparison are recognised together wifth the relatively
short observation period in the carbogen series but this data suggests a
possible advantage for carbogen for local control of bladder cancer.
022 STILBOESTROLIN THE MANAGEMENT OF REFRACTORY METASTATICPROSTATECANCER
DDeamaley1, ACapp1, JGadd2. RHuddart1.
1AcademicUnit ,2 BobChampionUnit, Royal Marsden Hospital, Sutton, Surrey,SM2
5PT.
Patients and Methods
48 patientswith metastatic Ca Prostate were prospectively entered into a phase11
study using Stilboestrol 3mg/day with 75mg aspirin/day. All patients had previously
been treated byorchidectomy or LHRH analogues +/-additional hormone
manoeuvres. LHRHanalogues werediscontinued on commencing Stilboestrol. All
patients had rising PSA ievels +/-subjectiveevidence of disease progression.
Stilboestrol treatmentwas 2nd linetherapy In 2 patients, and given as 3rd or 4th line
in 29 and 17 patients respectively. Stilboestrolwas continued until therewas
subjective (increasedlevels of pain/decreased performancestatus/requirement for
palliative radiotherapy)orobjective progression. The mean age atcommencement of
therapywas 67 years (range 48-86 years).
Results
1. Subjective response. 23/48 patients (48%) of patients showed benefit or disease
stability. Median duration of treatmentwas 4 months (range 0-18 months).
2. PSA response. Median PSA at the commencement of stilboestrolwas733ng/ml
(range 11 -12950ng/mr).39/48 patients had some fall in PSA ievel. In these 39man,
mean PSA fallwas 62% (range 10-99%)withmedian time to PSA nadir of 1 month
(range 2 weeks -12 months). 26/48men (54%)had> 50% fall in PSA. 12/48(25%)
had >80% fall in PSA.
Nosubjectivebenefitwasseen in 9/48 men who had rising PSAlevels (median
survival 1.5 months). 4/13men with < 50% fall inPSA hadsubjective benefit (median
survival 7months)comparedwith 19/26men with >50% PSA fall (mediansuial 15
months). Subjectivebenefit was seen in 11/12 patientswith>80% PSA fall (median
survival 18 months).
10 patients remain alive, and 3 are currently continuing to take Stilboestrol.
3.Toxicity. 5 patients experiencedthrombo-embolicevents onStilboestrol: 2 x
DVTs, 2 xpulmonaryemboli, and1xaxillay veinthrombosis. 4 responding patients
continued onStilboestrol whilst fullyantiooagulatedwithout furtherthrombotic
episodes. There were no deaths fromthrombo-embolic events. Additionally, 5
patientswith previous histories of thrombo-embolic events were fullyanticoagulated
whilst on Stilboestrol, with no further complications.
Conclusion:Stilboestrolprovides usefulpalliation in tp to 50% patientswith
refractory disease for amedian time of 5 months, with aminority of patients 7/48
havingprolonged responses of a year ormore.Provided each patient is
anticoagulated according to individual risk,thrombo-embolic events areuncommon.
024
JUSTIFICATION FOR USE OF CHEMOTHERAPY TO CONSERVE THE
TESTIS IN PATIENTS WITH GCC. RTD Oliver, J Ong, S Asterling. Medical
Oncology, St Bartholomew's & The Royal London Hospitals, West Smithfield,
London EC IA 7BE.
Given the association between declining sperm count and rising testis cancer
incidence and that more than 2/3rds ofgerm cell cancer patients have
diminished sperm counts and more infertility than matched controls, attempting
to conserve normal germinal epithelium in these patients isjustified if it does
not diminish cure. Recently, this unit has demonstrated that chemotherapy can
salvage the primary tumour bearing testis in some patients who present with
metastases or have a tumour in a solitary testis. Tojustify extending these
studies, data on delay and primary tumour size in a series of453 patients and
the effect ofchemotherapy on incidence oftumours in the contralateral testis is
reviewed and the study on the response ofprimary tumour to chemotherapy is
updated.
Between 1978-83 (n=I11)16% presented with delay equal or less than 2
months while in the period 1989-94 (n-190), 31% presented with delay less than
2 months. The average size oftestis tumours removed after less than 2 months
delay was 3.8cms while those removed after more than 6 months delay had a
median tumour size of5.3cms. The actuarial risk of a second germ cell cancer
in patients in complete remission at 5 & 10 years after BVP for metastases
(n=38), BEP for metastases(n=123), surveillance (n=72), adjuvant
chemotherapy(n=138) was 4.3% & 8.9%, 1.3% & 4.6%, 5.7% & 9.9% and
1.4% and 1.4% respectively. To date 46 patients have received testis
conserving chemotherapy. 30 had residual abnormality at completion of
chemotherapy and proceeded to orchidectomy. 16 have been followed for a
median of 7 years without orchidectomy with one second cancer at 12 years.
Given thepoor results ofhormone replacement in men, these findings suggest
that routine use oforchidectomy needs to be reconsidered. Neo-adjuvant
chemotherapy+/-partialorchidectomyisanalternative inpatients withtestis
atrophy or tumour in asolitary testis. To date 3 of6 patients with tumours in a
solitary testis have recovered spermatogenesis ad I has had 2 children.Oral Presentations 23
025 C-BOP/BEP FOR INTERMEDIATE AND POOR
RISK GERM CELL TUMOURS. A SINGLE IN-
STITUTION EXPERIENCE, DWO Tilsley, S Rivers, P Gill, D Mo-
reley, K Owen and MD Mason, Velindre Hospital, Cardiff CF4 7XL.
Objective: C-BOP/BEP has been reported previously as a prom-
ising regime in germ cell tumours at high risk ofrelapse with standard
therapy1. We report a single centre experience ofC-BOP/BEP in in
termediate and poor risk germ cell tumours.
Methods: Intensive induction is followed by consolidation with 3
sweep |1 2 2 3 x 4x|xxxx
C'isplatin 20mg m-2 xxxx>; xxxxx
Cisplatin 40mg m 2 x x
Carboplatin AUC x 2 x x
'Vincristine 2mg x x x x x x
Bleomycin 15mg/24 hrs xxxxx xxxxx
Bleomycin 15mg/15 mili x x x x
cycles of BEP on weeks 7, 10 and 13 (total Bleomycin dose 345mg).
Results: Between Dec. 93 and Dec. 96 15pt. (13 testicular teratomas,
2 seminomas) were treated. 9 were IGCCCG poor risk and 5 inter-
mediate risk. 14 were first presentations and 1 an 11 yr BEP relapse.
The mean age at start of C-BOP/BEP was 30(21 - 47) yr. 11/15
(733%) are alive and disease free with a median follow-up of 15(1 - 37)
months. 2 underwent surgery and only necrotic tumour was found.
2 received RT and 1 elective high close chemotherapy. 1 pt. died of
bleomycin lung and 1 of neutropenic sepsis. 1 tumour death occured
at 12 months from brain metastases. The main toxicities were leu-
copenia (58% G3, 25% G4), thlombocytopenia (25% G3 25% G4)
and neuropathy (50% GI, 33/V, G2). The GFR remained normal in
10/12 but in 2 was 69 and 79 ml m1in- at the eind of chemotherapy.
Conclusion: C-BOP/BEP appears effective in the treatment of in-
termediate and poor risk germ cell tumours. Further experience of
this regime in a multi-centre phase II trial is warranted.
Reference: Horwich A et al. Eur. J. Cancer 30A, 1607-1611 (1994).
027 AIM HIGH - FIRSTCONTACT S. Harris, B.W. Hancock, for the United Kingdom
Co-ordinating Committee on Cancer Research,
YCRC Dept ofClinical Oncology, Weston Park Hospital, Sheffield
There are no time limits imposed on investigators
wishing to participate in multicentre studies regarding the
interval between initial enquiry, submitting the study to their
local Ethics Committee and entering the first patient into the
trial.
The AIM HIGH study is a United Kingdom Co-
ordinating Committee on Cancer Research (UKCCCR)
multicentre, randomised study of observation versus adjuvant
low dose extended duration interferon alpha-2a in high risk
resected malignant melanoma.
Correspondence to and from the Clinical Trials Office
was used to establish time taken for investigators to submit the
protocol to their Ethics Committee after their initial enquiry, time
taken to inform the trial co-ordinator that approval had been
granted and time taken to enter the first patient into the study.
22 centres were studied. 9 Teaching Hospitals, 8 District
General Hospitals and 5 Specialist Oncology Centres. From
initial enquiry to submission to Ethics Committee takes an
average of 4 months. For the investigator to be notified that the
study has received approval takes 4 days but it takes 44 days
for the co-ordinator to receive written confirmation ofthis. After
approval, it then takes, on average, 101 days to recruit the first
patient into the trial.
Time taken from initial enquiry to entry of the first
patient has implications for the recruitment of a study which
could be delayed by as much as 7 months. Perhaps there should
be guidelines on reasonable time limits for this process.
026 ENTRY INTO CLINICAL RESEARCHSTUDIES: PATIENTS WHO REFUSE. Owen J; Abbey M;
Briggs T; Browne S; Hutchinson J; Wardle J; Coleman R &Hancock
BW. YCRC Dept. ofClin. Oncol., Weston ParkHospital, Sheffield.
Introduction. The right of a patient to refuse entry into a clinical
research study is anintegral part ofgood clinical research practice. We
describe an audit undertaken at Weston Park Hospital, Sheffield
investigating the numbers ofpatients who refuse entry, the types of
studies they were offered entry into and their reasons forrefusal.
Method. Patients who refused entry into a clinical trial were
evaluated between January 1996 and January 1997. Name, hospital
number, diagnosis, study referred for and reason for refusal were
documented.
Results. 421 patients were entered into research studies in the
specified period. An additional 80 patients refused entry, 36 (45%)
male, 44 (55%) female. 37 (46%) refused entry into adjuvant
treatment trials, 10 (13%) refused 1st line therapy studies, 13 (16%)
refused entry into 2nd line studies and 20 (25%) refused trials
involving supportive therapies. 29 (90%) of the trials refused were
randomised studies and 3 (10%) were open studies. Reasons for
refusal were:- 24 (30%) did not want chemotherapy (adjuvant
treatment), 6 (7.5%) did not want to be randomised, 20 (25%) had a
definite treatment preference, 9 (11%) refused due to the extra time
involved, 5 (6%) requested no further treatment (advanced disease), 7
(9%) did not want to be 'experimented on', 3 (4%) felt too unwell, 3
(4%) refused due to potential treatment toxicity, 1 (1%) was needle
phobic and for 2 (2.5%) patients the reasons were unknown.
Conclusion. Patients do not have to give a reason for their refusal to
enter a study but an indication ofwhy may be of benefit to clinicians
and allow us to tailor our process of obtaining written informed
consent accordingly.
028 RADIOTHERAPY FRACTIONATION SENSITIVITY: PROPOSALS
FOR A UKNATIONAL TRIAL. JR Yarnoldt JR Owen2, JM Bliss3,
SR Ebbs4, J. Reganl, B. Broad2, J. Davidsoni3, G. Harrinigtoti2, A. Ashltotl2
tAcadeitiic Radiotlierapy Unit, The Royal Marsdein NHS Trust, Sunoni, UK; 2Gloucestersltire Cetttre for
Cliilical Oncology, Clteltenltanit. Glos, UK; 3Section of Epideniiiology, linstitute of Caticer Research,
Sutton,UK;4Deparllllellt ofSturgery, Mayday Healthcare, Croydoni, UK.
The fractionation sensitivity of squamous cell carcinomas of the head
and neck and cervix uteri is relatively low with oa/, ratios comparable
to those of early reacting normal tissues. Very few data exist for
other tumour types, but those for soft tissue sarcomas, melanomas
and breast cancer suggest that fractionation sensitivities may be
greater in some tumour types. If this can be confirmed for breast
cancer, the possibility exists of simplifying radiotherapy schedules for
a very large population of patients without compromising treatment
benefit. Between January 1986 and July 1994, 915 patients were
entered into a trial after complete resection of early stage breast
cancer. Two 13-fraction schedules were compared with a standard
schedule of5OGy in 25 fractions to the breast. Two dose levels ofthe
13-fraction regime were selected (42.9Gy and 39Gy) with resulting
fraction sizes of 3.3 and 3.OGy respectively. The duration of
treatment was 5 weeks in all arms of the trial, followed by an electron
boost to the tumour bed of 14 Gy in 7 daily fractions. Assessments of
normal tissue damage in the breast were made by comparing the
appearances of annual photographs with the post-surgical
appearances. Of 735 patients with at least one follow-up
photographic assessment, the probability of a change in breast
appearance is significantly lower in patients randomised to 39Gy in 13
fractions compared to those allocated 5OGy in 25 fractions or 42.9Gy
in 13 fractions. At this time, no evidence is observed of a difference
between the 5OGy and 42.9Gy arms. It is therefore planned to extend
accrual of the trial to 2,500 patients in order to compare tumour
control and the frequencies of uncommon late side-effects.24 Oral Presentations
029 SERUM LIPIDS AND LIPOPROWINSIN
WOMEN WITH EARLY STAGE J3REAST
CANCER: EFFECTS OF HRT AND TAMOXIFEN.
J Marsden, NPM Sacks, M Worhington, D Crook. DVpt. ofSurgery,
The Royal Marsden Hospital &The Wynn Division, ICSM London.
The greatestnon-oncological cause ofmortality in brepst cancer survivors
is eardiovascular disease. HRT reduces cardiovascularrisk in part through
changes in lipids andlipoproteins. Tamoxifen lowers total and LDL
cholesterol levels, consequently, as part of a randomised study ofHRT
usein women with breast cancer, we investigated the combined effects of
tamoxifen and HRT on serwn lipids and lipoproteins.
METHODS: One-hundred postmenopausal women with early stage
breast cancer, experiencing vasomotor symptoms wereFandomised to
receive HRT (unopposed oestradiol or sequential combined therapy as
appropriate) or no HRT for 6 months. Fasting levels oftotal cholesterol,
triglycerides, LDL, HDL, HDL subtypes and apolipoproteins AL, All and
B were measured before randomisaton and after 6 months. Ofthe 86
women eligible for thislipidsub-study, 41 were current tamoxifen users.
RESULTS: At baseline, breast cancerpatients appeared to have high
levels oftotal and LDL cholesterol and apolipoprotein B compared to an
age andweight-matched group ofhealthy postmenopausal women.
Patients taking tamoxifen had normal levels. In breast cancer patients
HDL, apolipoprotein Al and II levels were normal at baselne,
irrespective oftamoxifen status. After 6 months, HRT had not altered
ILDL levels in the tamoxifen group, whereas these levels fell by 10-15%
(P<0.05) in those nottaking tamoxifen. HDL cholesterol levels increased
slightly in the tamoxifen group treated with unopposed oestradiol but
tended tofall in women given combined therapy, regardless oftheir
tamoxifen status.
CONCLUSION: The use of HRT in breast cancer patients already
treated with tamoxifen may not confer all ofthe protection against
cardiovascular disease expected from studies ofHRT in healthy women.
031 TAMOXIFEN: ASSESSMENT OF THE BALANCE OF
BENEFITS AND RISKS OF LONG-TERM TREATMENT.
Richard Gray, Kathleen Milligan, Lauren Padmore on behalf of the aTTom trial
stccringcomimilitte. CRC Trials Unit, Medical School, University of Birmingham.
The moost recent results from randomised studies comparing different
durations of tamoxifen treatment suggest that 5 years treatment is better
thani 2 years but substantial uncertainty remains about whetheri longer
than 5 years will provide any extra benefit. The NSABP B-14 study
comparing 5 years with 10 years found a higher recurrence rate with
longer treatment whereas a similar ECOG study has reported an
opposite finding. These apparently incompatible results may be at least
partly explained by the small numbers of events seen in these two
studies - compounded by the outcome-dependent early closure of the
NSABP study. A meta-analysis of the published data from tamoxifen
duration studies has been undertaken and the results of this, in the
context of the EBCTCG world-wide overview of tamoxifen trials, will
be presented. These data suggest that even longer treatment with
tamoxifeni will produce some additional net benefit but much larger
scale randomnised evidence is needed to confirm this.
aTTom is a large, uniquely, simple clinical trial that aims to provide
definitive evidence on the balance of benefits and risks of long term
tamoxifen by randomising many thousands more women between
stopping tamoxifen and continuing for 5 extra years. Because of
divergent clinical opinion on the minimum prior duration of tamoxifen
therapy, aTTom has adopted a pragmatic approach with randomisation
occurring at the point when both the clinician and patient become
un/iccrIiin whether- to stop or continue treatment. We surveyed UK
taimoxien prescribin gpatter-ns in 1993 and, againi, in 1997. The results
of this survey and the shift in UK breast cancer specialists minimum
treatment period, as evident from randomisations into aTTom, will be
piesented and discussed.
030 A NATIONAL RANDOMISED TRIAL OF HRT
IN SYMPTOMATIC WOMEN WITH EARLY STAGE
BREAST CANCER. J. Marsden & NPM Sacks on
behalf of the HRT Trial Steering Committee*
Observational studies ofHRT use in breast cancer patients have not shown an
adverse effect on survival however, a large randomised trial is urgently needed.
Although a previously reported randomised pilot studyt had ahigh accrual of
40% suggesting a national trial would be feasible, the opinions ofpatients (in
an R&D fundedproject undertaken by The Consumers' Advisory Group for
Clinical Trials and the Patient Involvement Unit, Mount Vemon Hospital) and
breast cancer surgeons (by postal questionnaire) were sought to identify issues
relevant to the design and successful implementation of a national trial.
Patient concerns about trial participation centred around principles ofgood
clinical practice and provision of information as well as the use ofHRT,
highlighting that reliance on accrual alone as a measure of successful trial
design is inappropriate as it does not elucidate factors influencing patient
choice. The majority (73.4%) of the 125 (i.e.50%)responding breast cancer
surgeons supported a randomised trial but only 28% ofthese admitted to
clinical uncertainty about whether HRT stimulates recurrence.
The proposed national trial aims to recruit 3,000 postmenopausal women with
early stage breast cancer, experiencing vasomotor symptoms, randomising
them to receive HRT or not for a minimum oftwo years. The main end points
are (1) disease-free survival and (2) quality oflife, follow-up being organised
so as to inflict a minimal additional workload clinics.
preliminary work has resulted in a considerable proportion ofthe trial design
being devoted to the support and information needs ofboth patients and health
professionals before, during and after the trial penrod and is thus anticipated to
optimise recruitment, save time and resources and is,in this respect, unique.
*Steening Committee Members (NPM Sacks, J Marsden, J Bliss, R A'Hern, J
Maher, IE Smith,MIW Whitehead, M Baum, D Riley, K Thirlaway, H
Thomton, M Dowsett, H Barton, Marie-Ann de Boeklin, D Fenlon, AKirby)
1. Marsden J. et al 1996. Br J Cancer (74) Suppl 18,SP14 p6.
032 NEAT-A NATIONAL BREAST CANCER STUDY OF
EPIRUBICIN+CMF VS CLASSICAL CMF AS
ADJUVANT THERAPY, HM Earl, CJ Poole, D Spooner,
C Jevons, and J Dunn. CRC Clinical Trials Unit, Univ. of Birmingham, B 15 2TA
The EBCTCG overviews of adjuvant chemotherapy for early stage
breast cancer have demonstrated a convincing reduction in the annual
odds of disease recurrence and of death with the addition of adjuvant
chemotherapy However, important questions of what might
constitute optimal adjuvant chemotherapy for early stage breast
cancer remain unanswered. One of the most pressing questions is the
role and optimal scheduling of anthracyclines. Studies by Buzzino
and Bonadonna found a significant benefit when anthracyclines were
given prior to CMF2'3. However, other studies of anthracycline-based
regimens have shown no statistically significant improvements in
disease free or overall survival when compared to classical CMF4.
NEAT (and its Scottish counterpart, SCTBG study of adjuvant
chemotherapy) is a multi-centre randomised trial of anthracycline-
containing chemotherapy exhibited in a block schedule followed by
sequential classical CMF, compared with classical CMF alone.
Epirubicin has been selected as the anthracycline of choice because
its anti-tumour effect is equivalent to that of doxorubicin but it has a
lower general toxicity, in particular the cardiac toxicity is about 50%
that ofdoxorubicin.
Target accrual is 1,000 in total, and already 150 patients have been
randomised by over 20 collaborators. As well as comparing the
effects of these two chemotherapy regimens on recurrence free and
overall survival, we shall also be assessing their impact of this trial
on clinical practice. We are asking clinicians at set time points their
expectations of the treatment effects and the first data available will
be discussed. NEAT is funded by the Cancer Research Campaign.
1. EBCTCG, (1992) Lancet: 339ppl-15, 71-85
2. Bonadonna G, et al. (1995) JAMA 273(7) pp542-547
3. BuzzoniR,etal.(1991)JCO9pp2l34-2140
4. Budd, GT,et al. (1995) JCO13(4)pp83l-839Oral Presentations 25
033 PHASE II TRIALS IN ANAL CANCER: 5-FU
AND CDDP IN ADVANCED DISEASE AND IN
EARLY DISEASE IN COMBINATION WITH
RADIOTHERAPY. HM Meadows, CM Ryan, J Houghton, JMA
Northover on behalfofthe UKCCCR Anal Cancer Working Party
The first- UK randomised trial comparing radiotherapy alone with
chemoradiation in patients with anal cancer found a significant
advantage in local control for patients on the combined modality
treatment'. However the results also demonstrated that these patients
have a poor prognosis with about 50% dead by 5 years and, ofthose
dying ofthe disease, more than 40% had distant metastastes.
To improve this outcome we planned to run a further phase III trial
using cisplatin (CDDP) and 5-fluorouracil (5-FU). To evaluate the
toxicity ofthese agents two phase II trials have been initiated. The first
was to evaluate 4 cycles of5-FU (1 g/m2 per day) and CDDP (25 mg/nV
per day) both for 4 days, given every 3 weeks, in patients with
advanced disease. Eleven patients have been recruited; median age 49
(38-66) years. Seven patients reported toxicity (4 neutropaenia > grade
3; 2 WBC . grade 3; 2 alopecia; 1 stomatitis) and there was 1
treatment-related death.
A second phase II trial has evaluated the same doses ofchemotherapy
given in one or two courses concomitantly with radiotherapy (40 Gy in
20 fractions in 4 weeks or 45 Gy in 25 fraction in 5 weeks) in newly
diagnosed patients. 25 patients have been entered; median age 53 (36-
71) years. In the 16 patients for whom response information is
available, 13 had a complete response and 3 a partial response. No
severe toxicity was reported in 10 patients. Ten patients reported skin
reactions but these were only severe (2 grade 3) in 4.
A further phase II trial is underway to evaluate chemoradiation
incorporating mitomycin as well as 5-FU and CDDP.
1. UKCCCR Anal CancerWorking Party. Lancet 1996 ;348: 1049-54
035 SITES OF RECURRENCE AFTER LIMITED
NECK IRRADIATION (XRT) FOR CANCER OF
THE SUPRAGLOTTIS AND TONSIL. J.H. Hay, S.M. Jackson,
A.D.Flores, L.M. Weir, F.W.L. Wong, C. Schwindt, B. Baerg.
BC Cancer Agency, Vancouver Cancer Centre, 600 W 10th
Ave, Vancouver, British Columbia, V5Z 4E6, Canada.
Aim: to analyse the sites of failure following XRT for scc
tonsil and scc supraglottis when the target volume included
only clinical disease and the next echelon of lymph nodes.
Study gogulations. All received at least 5OGy, most 6OGy in
2.4Gy fractions. Supraglottis:121 patients (88% of all
radically treated patients) treated between 1985 & 1992, all
with opposed lateral fields, none had the posterior neck
irradiated above the limits of cord tolerance. 15 had UICC
Stage I disease, 25 St II, 34 St 1II, 47 St IV. Average field
lengths were St I: 7.2cm, St II: 7.5cm, St III: 8.5cm and St
IV: 9.2cm. Tonsil 88 patients treated with unilateral XRT in
the years 1975-1980 and 1988-1993. The two cohorts had
the same local control and survival rates. 8 were UICC St I,
28 St II, 34 St III and 18 St IV. Average field lengths were
St I: 7.25cm, St II: 8.3cm, St III: 9.3cm and St IV: 11cm.
Results: Overall survival and local control compared
favourably with the reported literature.
Site of grogression or recurrence
Primary Nodes Both
Sugraglottis 30 12 10
Out of field 1 4
Tonsil 21 9 4
Out of field 0 2
Conclusion. Limited field XRT of this sort results in nodal
recurrence rates that are very similar to those obtained by
wide field XRT and are lower than those reported after small
field XRT. In-field locoregional failure is the major problem.
034 THE INCIDENCE AND EFFECT OF PROLONGATION OF
OVERALL TREATMENTTIME IN PATIENTS WITH
CARCINOMA OFTHE LARYNXRECEIVING RADICAL
RADIOTHERAPY IN SCOTLAND.
A GRobertson(l), C Robertson(2), H M MacDougall(3), HYosef(l), JDewar(4), T
Elia(5), D Hurman(6), C Clark(7), C Peronne(2). 1) Beatson Oncology Centre,
Western Infirmary, Glasgow, GIl 6NT, Scotland. 2) EIOMilan. 3) Radiotherapy
Dept,Western General, Edinburgh. 4) RadiotherapyDept, NinewellsHosp. Dundee. 5)
Radiotherapy Dept, Inverness. 6) Radiotherapy Dept, Foresterhills Hosp. Aberdeen. 7)
SCTN ISD Edinburgh.
1071 patients with cancer ofthe larynx weretreated in the five Scottish Cancer
Centres between 1986 and 1990, 1994 and 1995 with radical radiotherapy. The
male to female ratio was 3.85:1. Data relating to tumour stage, field size and
treatment schedule were all recorded. 97% weretreated wearing a BDS. Three
Centres treated patients radically over 4 weeks and the other two over 5 and 6
weeks. After allowance for patient characteristics, stage ofdisease etc. there was
no significant difference in outcome forpatients treated atthe five centres.
Patients with tumours arising inthe (lottic region had a better outcome than
those with tumours arising in the supraglottic region (67-84%0-v-26-55%).
65%ofpatients hadtheir treatment prolonged by aday or more. 50% ofthese
interruptions were due to machine servicing ormachine breakdowns. Other
reasons included replanningtreatment, transportproblems andpatient illness.
Survival analysis ofthe complete data (912 cases) gave a five year survival for
T1-78%, T2-66%, T3-46%, T4-38%. Linearquadratic analysis fortheglottic
node negative showedthat unscheduled prolongation oftreatment affected
overall tumour control. Prolongation by a day is statistically significant. In many
cases a one day gap resulted in a prolongation of3 days due to the addition ofa
two day weekend gap. The effect ofprolongation ofoverall treatmenttime by 4
days is very significant.
036 IMPACITOFCONFORMALRADIOIERPY ON
'IEATMENTOFHEADANDNTIXCANCER,
MHRisn*2 JCnway',CAnny2 GBrwn2.
LGriftl and S Ot', lDeqxntof Medica Physics ai Cil EBn ing
2YCRCDq tofCrndOo,WesionPakHospilShlidd
Introduction: the treatment of head and neck cancer with radiotherapy
is difficult because of the low tolerance to radiation of many structures
which are close to the target volume. 3D conformal radiotherapy is
being introduced in an effort to improve the therapeutic ratio in this
situation.
Methods: conformal 3D plans produced via CT studies and utilising
Multileaf Collimation (MLC) of each field are compared against
conventional planning techniques where planning target volumes
(PTVs) are defined from orthogonal radiographs and where simple
shielding methods are employed. Analysis of cumulative dose volume
histograms (CDVH) for both plan types, enable four score functions to
be defined, ie gradient (So), overdose (s1), underdose (s2) and regret
fraction (Rf). The regret fraction is defined as the ratio of the PTV to
the Treated Volume enclosed by the Minimum Tolerance Dose (Dmin)
and indicates the degree of conformality of the plan. The other score
functions reflect the uniformity of dose, overdose, and underdose
volumes relative to the tolerances allowed in the PTV. The dose to
critical organs are compared for both conformal and conventional
plans.
Results: 37 patients have been studied. An expected improvement in
the degree ofconformity using MLCs was demonstrated in 70%. 60%
of these patients plans showed a reduction in the overdose volume for
the conformal plans. However, half of all the plans exceeded the
tolerances for overdose in the target volume. 40% of plans showed
increase in the underdose volume when multileaf collimator fields are
employed but remained within the limits decided by the clinician.
Those plans that had poor underdose scores using conventional
planning were improved using MLC fields. 70% of plans indicated a
reduction in mean dose to critical structures.
Conclusion: This modified scoring system provides a means tojudge
conformal planning techniques against the conventional methods that
have previously been employed.26 Oral Presentations
037 PHASE I DOSE ESCALATION TRLAL OF INTRA-
TUMOURAL INJECTION OF AN ONCOLYTIC
E1B ATTENUATED ADENOVIRUS, ONYX-015, IN PATIENTS WITH
RECURRENT p53(-) SQUAMOUS CELL CANCER OF THE HEAD AND
NECK I. Ganly' 2, D. KiM6. G.I.Rodriguez3, D. Soutar2, G. Eckhardt3, R. Otto4.
A.G.Robertson', 0. Park', M.L. Gulley5, M. Kraynak5, C. Heise6, C.Maack6,
P.W.Trown6, D.D. Von HoffW, S.B.Kaye'. 'University Dept of Medical Oncology,
Beatson Oncology Centre, Glasgow; 2Dept of Plastic and reconstructive surgery,
Canniesburn hospital, Glasgow, Scotland; 3Cancer Therapy and Research Center,
San Antonio,TX78229; 4The University of Texas Health Science Centre at San
Antonio, TX 78284; 5Audie L. Murphy VA Hospital, San Antonio,TX78284;
6ONYX Pharmaceuticals, Richmond, CA 94806.
OBJECTIVE: ONYX-015 is an adenovirus which lacks the EIB gene coding for
the 55kDa protein. This allows it to selectively replicate and lyse cells with non-
functional or mutant p53. The objective of this study was to determine the safety
andefficacy ofdirect intratumoural injection ofONYX-O15.
METHODS: Patients with recurrent head and neck cancer were recruited. The
p53 status of the tumours was assessed by iinmunohistochemistry and gene
sequencing on a single core biopsy taken from the recurrent tumour. Only
patients with abnormal p53 as assessed by IHC were treated. Patients received
direct intratumoural injection ofONYX-015 over 5 cohorts with a minimum of 3
patients per cohort. Vital signs were monitored for 2 days postinjection and
patients were assessed twice weekly for toxicity. Tumour response was assessed
both clinically and radiologically 4 weeks postinjection. Patients with stable
disease had repeat injections done every 4 weeks. Postinjection biopsies at days 8
and 22 were assayed for viral replication by in situ hybridisation ofviral DNA.
RESULTS: 19 patients were treated - Spts at 107pfu, 4 at 108 pfu, 4 at 109pfu, 3
at 3xlO9pfu and 3 at 10'°pfu. All patients had abnormal p53 as judged by IHC.
13/16 tumours for which p53 sequencing results are available had mutations in
exons 5-9. No significant toxicities were observed. Vital signs remained normal
following injection. 5 patients received repeat treatment(up to 4 cycles). 4 patients
had significant necrosis of injected tumours both climcally and radiologically.
Viral replication was detected in postinjection biopsies at the 10'°pfu dose level.
CONCLUSIONS: Intratumoural injection of recurrent head and neck squamous
cell cancer with ONYX-015 is safe. In addition, clear biological effects oftunour
necrosis are seen. Phase It studies are planned in order to better define the
efficac3 ofONYX-015.
039 CAN ADJUVANT PILOCARPINE PREVENT POST
RADIATION XEROSTOMIA? MEB Powell, HJ Cladd,
MlSaunders, Marie Curie ResearchWing,MountVernon Hospital,Northwood,
Middx UK.
Aim Post-treatment xerostomia is an important toxicity of head and neck
radiotherapy, leading to an increase in dental caries, oral infections, and
discomfort for patients. This prospective, randomised, double blind placebo
controlled trial evaluates the efficacy of oral pilocarpine given dunng radiation
treatment in reducing theseverity ofsalivaryglanddysfunction.
Methods Twenty four patients with primary head and neck tumours,
scheduled to receive radical radiotherapy were randomised to receive either
placebo orpilocarpine (5mg TDS) to be taken from day 1 of treatment for 12
weeks. Baseline measurements of whole and stimulated parotid saliva flow
rates were taken prior to treatment and at weeks 1, 8, 12, and 24 following
irradiation. In addition, quality of life was evaluated using a questionnaire.
Results Salivary function was impaired in both groups within 1 week of
starting treatment, with flow rates dropping by as much as 80%. Over the 6
month observation period measurement of whole saliva and parotid saliva
flow showed no significant difference between the groups. Quality of life
assessment again did not show a difference between the groups. Five
patients discontinued tablets due to side effects, 2 taking pilocarpine due to
sweating and 3taking placebo because of nausea.
Conclusions Pilocarpine given adjuvantly during radiotherapy neither
improvessalivary function norgives symptomatic relief.
038 CONTINUOUS HYPERFRACTIONATED ACCELERATED RADIOTHERAPY(CHART)AND BRACHYTHERAPY IN
EARLY ORAL CA\VITYAND) OROPHARYNGEAL CARCINOMAS:
A PROSPECTIVE REVIEW OF OUTCOME AND MORBIDITY. Goodchild
K,SaundersMl,Powell MEBP,Hosidn PJ. MCRW,Mount Vemon Hospital,Northwood,UK.
T2 NO squamous cell carcinomas of the oral cavity may be treated with
conventionallv fractionated extemal beam radiotherapy followed by an
implant. In this pilot study CHART to 40.5Gy was followed immediately by a
low dose rate implant. This technique enabled the implant to be performed
easily as the tumour margins were clearly defined in the absence of mucositis.
Treatment was completed in 12 days.
Twelve patients aged 41-78 years were treated. Eleven had T2 NO MO
squamous cell carcinomas and one was post-operative with no residual
macroscopic disease.
The primary and first eschelon lymph nodes received 40.5Gy in 27 fractions.
prescribed to the intersection point (1.5Gy/# three times daily including the
weekend). CHART was commenced on a Monday moming and completed by
the following Tuesday evening. A caesium or iridium implant was carried out
the next moming; doses ranged from 17.5-25Gy at 0.5cm over 48 hours.
Median length of follow-up is 39.5 months (range 6-74 months). All patients
developed confluent mucositis which healed completely by three months.
Long term morbidity in the skin and mucosa was minimal. Three patients
developed a moderately dry mouth which persisted in two.
One patient was lost to follow-up, 10/11 patients were in complete clinical
remission at three months. In longer follow-up 9/11 patients were locally
controlled. Median disease-free survival was 36 months and median overall
survival was 39.5 months.
We conclude that this scheduling of therapy has minimal long term morbidity
with good local control and survival rates.
040 OVERCOMING RADIORESISTANCE USING
ULTRA LOW DOSES, S. Short and M.C. Joiner, Gray Laboratory
Research Trust, Mount Vernon Hospital, Northwood, Middx HA6 2JR.
The phenomenon of low dose hyper-radiosensitivity (HRS) has been
demonstrated in a number ofhuman tumour cell lines and in some
tumours and normal tissues in vivo. It produces increased cell kill per
unit dose below one gray. The corresponding increase in radioresistance
at higher doses is thought to be related to induced DNA repair following
radiation which is only triggered above a certain dose. Previous work
has suggested that these effects may be more apparent in more
radioresistant cell lines (compared to both sensitive cell lines and normal
tissues). Ifthis is the case the use ofvery low doses per fraction may
offer a real therapeutic gain over conventional treatment in some tumours
by exploiting their low dose hypersensitivity. We have looked for HRS
in radioresistant human cell lines using a microscopic cell analyser to
accurately determine cell survival at very low doses (down to 0.05 Gy)
in vitro. We have confirmed the effect reported previously in the human
bladder carcinoma line RT112 and have now demonstrated HRS in a
newly tested glioblastoma line, T98G. A second radioresistant glioma
cell line, U-373 which we have also newly tested did not show the effect;
this now indicates a less straightforward relationship between
radioresistance to conventional doses and low dose
hypersensitivity/induced radioresistance. These data nevertheless suggest
that for some tumours a workable therapeutic regime could be based on
'ultra-fractionation' i.e. doses <1 Gy per fraction using multiple fractions
per day, which may overcome their resistance to conventional therapeutic
regimes.Oral Presentations 27
041 NORMALTISSUERADIOSENSITIVITY:THE
ROLE OF DNADAMAGE ASSAYS
C.J. Orton', A.E. Kiltie2,A.Ryan2, C.M.L. West2,
J.H. Hendry2, R.D. Hunter', S.E.Davidson', 'Dept. Clinical Oncology,
Christie Hospital,2Dept. ofExperimental Radiation Oncology, Christie
CRC Research Centre, Manchester M20 4BX
Introduction: Several promising correlations have been reported
betweenfibroblast radiosensitivity in vitroasmeasured by a clonogenic
assay and the severity of late normal tissue reactions. There is
increasing interest in more rapidtests ofradiosensitivity, in particular
thosethatmeasureDNAdamage. There havebeenfewreports studying
the relationship between the different methods available. Inthis work
a comparison has been rnade offibroblast radiosensitivity measured
using a clonogenic assay and three gel electrophoresis techniques;
pulsed field, graded voltage and constant voltage gel electrophoresis.
Materials: Eleven fibroblast strains were studied comprising two
radiosensitive human strains andnine strains established from vaginal
biopsies from patients with carcinomas ofthe cervix prior to a radical
course of radiotherapy. Methods: Cells were labelled with tritiated
thymidine for 72 h and grown to confluence. After 10 days they were
irradiated at a dose rate of 1.87 Gymin-'to doses between 30 and 180
Gy. Residual DNA damage at 24 h was measuree' as the fraction of
activity released (FAR) into the gels. Results: For all three methods
there were highly significant correlations between cell surviving
fractions at 2 Gy and the slope of FAR, r>0.88, p<0.01. The
correlations among the three gel electrophoresis methods were also
highly significant, r>0.89, p<0.01. Conclusions: The future ofDNA
damage assays in predicting normal tissue radiosensitivity appears to
be promisinrg.
043
CELLCYCLE ARREST, APOPTOSIS AND RESPONSE
TO IRRADIATION AND ANTIBODY IN LYMPHOMA CELLS.
T.M.llidge, M.S.Cragg, MJ.Glennie; Lymphoma Research Laboratory,
University ofSouthampton. S0166YD. UK
The cellular response to DNA damage following irradiation ofp53 mutant
lymphoma cell lines involves a cell cycle arrest at the G2/M check-point; priorto
the appearance of apoptosis and irradiation can influence antibody induced
apoptosis. All 10 lymphoma cell lines studied demonstrated upto a four fold
peak increase in the number ofcells in G2/M which occurred 18 to 24 hours after
irradiation and prior to apoptosis. The kinetics of apoptotic cell death varied
considerably and correlated with the rapidity ofexit from the irradiation induced
G2/M arrest. The loss offunction ofwild-type p53 and the time period elapsed
in G2/M arrest following irradiation, appear to predict radiosensitivity. Our
results taken together strongly suggest that apoptosis is involved in the increased
radiosensitivity of cells which exit rapidly from the G2/M checkpoint.
Lymphoma cells which stay longer in G2/M were more resistant to apoptosis
than cells which exited faster. Abrogation of the G2/M arrest by Caffeine
produces increased radiosensitisation of p53 mutant radioresistant Burkitt's
lymphoma cell lines byproducing increased irmdiation induced apoptosis.
DNAdamage by increasing doses ofirradiation, appears to inhibit the
early onset ofanti-j (anti-B cell receptor) but not anti-CD20 induced apoptotic
cell death. Anti-CD20 antibodies when combined with irradiation demonstrate
an additive effect in some cell lines. This finding ofan antagonistic effect rather
than an additive effect with irradiation andanti-g antibodies was unexpected and
suggests that the signals for G2M arrest initiated by irradiation induced DNA
damage can inhibit orover-ride theprogrammed cell death initiated byCeramide
following stimulation ofthe B-cell receptor.
042 RADIATIONINDUCEDCELL-CYCLE
DELAYS INASYNCHRONOUS
POPULATIONSOFNORMALFIBROBLASTS
ARE RELATED TO RADIOSENSITIVITY. C.J.Orton', J.Berry2,
'Dept. ClinicalOncology, ChristieHospital,2Dept. MedicalPhysics and
Instrumentation, ChristieCRC ResearchCentre,ManchesterM20 4BX
Introduction: Itispossibletostudy irrdiationinducedcell-cycledelays
inasynchronouspopulations withbivariateflowcytometry. Materials:
Twelve normal human fibroblast cell strains were studied. Methods:
Confluentcells were irradiated andthen plated out at lowcell density
for 72 hrs, before performing cell-cycle analysis. Results: G2 block
following irradiation is measured by the cmptying ofthe original G2
compartment; in the most radioresistant cell strains maximum block
occursat2Gywhereas inthe radiosensitive strains this does not occur
even after 4 Gy. The proportion of cells which cycle following
irradiation correlates with the cell survivingfractions at 2 Gy, SF2,
r=-0.86, p=0.026, at 2 Gy. The accumulation ofcells in the first G,
compartmentfollowingirradiationisgreaterinradioresistant cells than
in radiosensitive cells; at 4 Gy this relationship reaches significance
when correlated with SF2, r=0.81, p=0.05.The percentage of cells
enteringtheG2compartment inthe firstcycle is the same irrespective
ofwhetherthe cells are irradiated or not. In cycling cells G2/M delay
measuredbythe ratioofthe percentage ofcells in G2in the firstcycle,
tothepercentageofcells inG,inthe second cycle, correlates with SF2,
r=-0.89, p=0.03 at 2 and 4 Gy. Conclusions: Irradiation induced cell-
cycle delays correlate with radiosensitivity.
044 IRRADIATION MODIFIES KERATINOCYTE MIGRA- TION INRESPONSETOGROWTHFACTsORS AND
CYTOKINES IN VITRO S.Pledge'. H.Robson',
E. Anderson' and J.Hendry2.'Clinical Research Dept, Christie
Hosp,2Exp.Rad.Biology,Paterson Inst.Cancer Res,Manchester, UK.
(S.P.now YCRC Ac.Dept Clin Onc,Weston Park Hospital, Sheffield)
Many radiotherapy patients experience acute reactions in
epithelial tissues which can result in treatment delay or dose
reduction. We have investigated methods of ameliorating these
acute reactions using cytokines and growth factors to radio-
protect the normal tissues, maximise cellular repopulation and
promote keratinocyte migration into denuded areas.
Cultured human keratinocytes were used for experiments
at passages 2-4. The effects of epidermal growth factor (EGF),
basic fibroblast growth factor (bFGF), keratinocyte growth
factor (KGF) and transforming growth factor I3 (TGFP3) on
keratinocyte proliferation and migration under normal
conditions and after irradiation were determined.
Proliferation was measured using a 96 well plate colorimetric
assay of cell density and capacity for migration was assayed
using a phagokinetic track method [Albrecht-Buehler G., Cell
(1994), 11, 395] with and without prior irradiation (5Gy y
radiation). TGF33 was added before irradiation of the cells
whereas the other factors were added after. The effects of the
cytokines on cell cycle distribution of the keratinocytes and
expression of the EGF receptor with and without irradiation
were determined using flow cytometry and ligand binding
analysis.
Both EGF and KGF stimulated proliferation whereas TGFJ3
inhibited it whether the cells were irradiated or not. The
results of the migration experiments showed that EGF was the
only factor that could significantly enhance migration.
Irradiation on it's own slightly reduced migration, however,
when administered before addition of the factor, irradiation
significantly enhanced the motogenic effects of EGF on the
keratinocytes. This may be related to induction of EGFR
expression by irradiation as has been reported previously
[Peter R.U. et al, Radiation Res (1993) 136, 65]. Alternatively,
the keratinocytes may be able to migrate more easily when
they are arrested in G2 as after irradiation.28 Oral Presentations
045 IS HUMAN TUMOUR BLOOD FLOW INFLUENCED BY CARBOGEN
AND NICOTINAMIDE? 1MEB Powell, 2SA Hill, 1MI Saunders,
IPJ Hoskin, 2DJ Chaplin, 'MCRW, 2Tumour Microcirculation
Group, CRC Gray Lab, MountVernon Hospital, Northwood, UK.
Aim Hypoxia is recognised as a mechanism of treatment resistance to many
anticancer therapies. Modification of the tumour microenvironment by
increasing pedusion andoxygenation of tumours mayimprove on the success
of these treatments. To address this clinical trials are underway to evaluate
nicotinamide and carbogen (95%02, 5%CO2) in combination with accelerated
radiotherapy. Using laser Doppler probes to measure microregional tumour
blood flow, this study examines the influence of nicotinamide and carbogen on
tumourperfusion.
Methods Ten patients with advanced cancer were studied. Nicotinamide
(80mg/kg) was given orally and 60 minutes later up to 6 probes were
inserted intothetumour. One hourof readings were taken priorto 10 minutes
of carbogen and 10 further minutes breathing room air. Results were
compared with a similargroup of 8 control patients notgiven nicotinamide but
who breathed carbogen.
Results In 44 microregions analysed, 33 (75%) showed perfusion
fluctuations of .50%, and 20 (44%) by .100%. This compared with the
control group in whom 62% and 27% of microregions varied by .50% and
.100% respectively. Perfusion increases outweighed decreases by 1.3 with
nicotinamide and 1.2 in the controls. After 5 and 10 minutes of carbogen
tumour perfusion increased by 17% (p<0.004) and 22% (p<0.001) with
nicotinamide and 0% and 1% inthe control group.
Conclusions Pre-treatment with nicotinamide made little difference to
random blood flow fluctuations seen in controls. However, with nicotinamide
plus carbogen, tumour perfusion more reliably increased compared with
carbogen alone. This may have important therapeutic implications by
improving response to treatment and allowing better delivery of systemic
agents.
047 OVARIAN CANCER: IMPROVEMENT IN
SURVIVAL IN SCOTLAND WITH PLATINUM
CHEMOTHERAPY. E J Junor on behalf of the
Scottish Cancer Therapy Network.
Object To determine changes in management and survival
of patients with ovarian cancer in Scotland Between 1987 and
1993.
Methods Retrospective case record review of all cases of
ovarian cancer registered to the Scottish Cancer Registration
Scheme in 1987 and 1993. Data extracted with regard to
demography, treatment and outcome. Cox's proportional
hazard model was used to elicit independent treatment
variables while adjusting for prognostic variables.
Results 1040 patients registered of whom 931 eligible for
study. The two year survival for all patients in 1987 and 1993
were 38.0% and 42.8% respectively. For patients over 64
years, 2 year survival was 23.4% in 1987 and 33.6% in 1993.
Age, stage, histological group, degree of differentiation and
ascites were independent prognostic variables.
Compared to 1987 there has been a marked increase in the
use of platinum in patients 64+ in 1993. After adjusting for
the five 'biological' prognostic variables, speciality of the first
hospital contact, specialty of operator, residual disease and
attendance at a multidisciplinary clinic, there remained a
statistically significant (P <.006) difference in survival for
patients 64+ years between 1987 and 1993. This difference
was entirely due to platinum chemotherapy.
Conclusion All the improvement in survival in patients over
64 years between 1987 and 1993 can be accounted for by the
increased prescription of platinum chemotherapy.
046 FUNCTIONAL IDENTIFICATION AND PREUMINARY BIOLOGY
OFANOVELOVARIAN CANCERTUMOURSUPPRESSOR
GENE (TSG) ON CHROMOSOME 11q24. H.Gabrael, J. E.
V. Watson1, K. J. Taylor1, G. J. Rabiasz1, A. A. Ritchie1, C.M. Steel2, J.
F. Smyth1 and D. J. Porteous2, IICRF Medical Oncology Unit, 2MRC Human
Genetics Unit, Western General Hospital, Edinburgh.
We have previously reported that LOH of an 8.5 Mb region on 11q23-q24,
is associated with advanced FIGO stage and poor survival in ovaran
cancer(Gabra et al Cancer Res56, 950-954, 1996).
We used a mouse Ag somatic cell hybrid (556.1.5) to transfer a normal
human chr 11 by microcell mediated chromosome transfer into OVCAR3 (a
poorly differentiated ovarian adenocarcinoma cell line with chr 11
rearrangement). Transfer of whole human chrl1 was confirmed by
chromosome paint, primed in-situ hybridisation (PRINS), and
microsatellite analysis. Fourteen microcell hybrid clones (MHCs) were
derived from 5 experiments in which chr 11 was transferred into a
HygromycinR-tagged OVCAR3 subline. The immortalised parental
phenotype was retained in all chr 11 MHCs. Significant in-vitro and in-
vivo growth inhibition was noted for chr 1I MHCs compared with control
parent HygR OVCAR3 and control MHCs with null chromosome transfers.
Flow cytometric analysis for cell cycle distribution and Annexin-V assay
for apoptosis suggested that the observed inhibition was not mediated by
these processes.
Matrigel invasion assays demonstrated significant reduction in
invasiveness of the chr 1I OVCAR3 MHCs that retained distal 11q
compared with MHCs that had lost distal 11q and OVCAR3 controls.
Further analysis demonstrated that this was associated with inhibition of
attachment and spreading to laminin coated plastic and inhibition of cell
migration associated with a collagen IV or fibronectin haptotactic signal.
Integration of microsatellite mapping data from the MHCs with that of LOH
from the patients has reduced the size of the interval housing the TSG to
4.5 Mb.
The phenotypes derived from the above techniques are being used to
isolate this novel and prognostically important tumour suppressor gene by
cDNA difference cloning methodology.
048 ASSESSMENT OF TUMOUR REGRESSION RATES
DURING RT FOR CA CERVIX USING SERIAL MRI
L T Tan C S Romaniuk, J Brunt, B Jones
Clatterbridge Centre for Oncology, Wirral.
The potential importance of tumour regression rates in determining the optimum
timing of brachytherapy in relation to external beam RT in order to achieve
maximum tumour cell kill has been explored in mathematical modelling exercises.
However, before it is possible to evaluate the effect of tumour regression rates on
tumour control in clinical practice, a reliable method of estimating the tumour
regression rate is required. A prospective study has therefore been undertaken to
assess the feasibility of estimating the regression rates of cervical carcinomas during
radiotherapy using serial MRL
Eleven patients with FIGO Stage IB-IIB cervical carcinoma have been included in
the study. Each patient underwent a routine staging MR examination ofthe abdomen
and pelvis prior to commencing RT followed by serial MR scans of the pelvis at
weekly intervals during RT. The staging and serial pelvic examinations included
sagittal and oblique axial T2-weighted fast spin echo pulse sequences using long
repetition times (range 220)0-3500 msec) and echo times (1150 msec) at 0.5 Tesla
(Philips Gyroscan T5-ll). Images were acquired using 6 mm contiguous slices, 179 x
256 matrix, 35(1 mm field of iew and 6 signal averages. Constant scan parameters
were used in all examinations performed on an individual patient. Tumour volumes
were estimated using 2 methods bv a radiologist and an oncologist:
1. Planimetry The tumour mass was manually outlined on serial images using the
manufacturer's computerconsole and standard measurement software.
2. Stereolo2g Tumour volumes were estimated on the same images as for
planimetrv using the unbiased stereological method ofmanual point counting.
Tumour volume regression rates were determined from a semi-logarithmic plot of
sequential tumourvolumes against time using linear regression analysis.
Initial tumour volumes ranged from 6 cm3 to 200 cm3. Tumour regression occurred
within days ofcommencing radiotherapy and followed a negative exponential function
with time. Estimated tumour volume regression rates ranged from 2% per day to 20%
perday. There wsas no correlation between the estimated tumour regression rates and
the initial tumourvolumes. A minimum of4 scans was required to estimate the tumour
regression rate with reasonable precision. Similar regression rates were obtained
using both planimetry and stereology. There was no significant intra-observer or
inter-observer variabilitv in the estimated regression rates.
The studv has shown that it is possible to estimate the rate of tumour regression
during RT forcarcinoma ofthe cervix with reasonable precision using serial MRLOral Presentations 29
049 TUMOUR ANTIGEN EXPRESSION IN OVARIAN
TISSUE AM Gillespiel. S Rodgersl,AP Wilson2, AKMurrayl,
RC Rees3, J Tidy4 and REColemanI.IYCRC Inst Cancer Studies
& Dept Clinical Oncology, University of Sheffield, Sheffield, 20ncology Research
Laboratory, Derby City Gen. Hospital, Derby, 3Dept. Life Sciences, Nottingham
Trent University, Nottingham, 4Dept. Obstetrics & Gynaecology, University of
Sheffield, Sheffield, UK.
Ovarian cancer accounts for 6% of female cancer deaths. In the near
future novel treatment modalities may contribute to an improved
prognosis for women diagnosed with this disease.
Antigen Specific Immunotherapy with MAGE peptide products may be
one such therapy. It is known that MAGE 1-4, 6 & 12 genes are
expressed in some human cancers. MAGE 1 & 3 are targets for specific
immunotherapy as they encode peptide antigens -" tumour antigens "-
which are presented in association with HLA class 1 molecules and are
recognised by cytotoxic T lymphocytes.
To determine if ovarian cancer patients would be suitable for MAGE-
peptide vaccine based immunotherapy, the frequency of expression of
the MAGE 1-4 genes in ovarian tumours was assessed using Reverse
Transcription Polymerase Chain Reaction (RT-PCR) and product
verification with digoxigenin-labelled oligonucleotide probes specific
for each MAGE gene. In addition the frequency of expression of more
recently discovered tumour antigens (BAGE, GAGE-1,-2 and GAGE-
3,-6) was established using RT-PCR and ethidium bromide staining.
To date in this study 15/28 ovarian cancer specimens have expressed
MAGE 1, including 10/13 serous adenocarcinomas. In addition 13/21
benign pathological ovarian lesions studied also expressed MAGE 1,
including simple cysts, cystadenomas and adenofibromas. No MAGE
expression was detected in 10 normal ovarian specimens. Expression of
other tumour antigens was rare.
This study indicates that serous cystadenocarcinomas may be suitable
candidate tumours for MAGE peptide immunotherapy, whilst previous
assumptions regarding the role of MAGE genes in carcinogenesis is
questioned by our finding of expression in both benign and malignant
tissue.
051 A PHASE 11 STUDY OF EPIRUBICIN, CISPLATIN AND
PROLONGED VENOUS INFUSIONAL 5-FU (ECF) IN
RELAPSED EPITHELIAL OVARIAN CANCER (EOC).
FY Ahmed, PN Mainwaring, DM King, RP A'Hem, M Ramsden, B McLaren, J
Mansi, P Harper, M Slevin, H Thomas, ME Gore for The LGOG
The probability of response to chemotherapy following relapse in
patients with EOC is related to the treatment- free interval, for
instance response rates range between 17-26% for patients (pts)
rechallenged with platinum-based chemotherapy within 12 months
(Gore et al 1990, Markman et al 1991). Results with newer phase II
agents such as paclitaxel, topotecan, altretamine, and gemcitabine, are
not substantially better than this. ECF has been evaluated in a number
of solid tumours, most notably in gastric and breast cancer. We have
assessed the efficacy of this regimen in relapsed EOC. Eligibility
criteria were; performance status (PS) 0-2, relapse following one prior
platinum-based chemotherapy regimen or not more than two prior
regimens and a treatment-free interval of less than 12 months. 55 pts
were entered and their characteristics were: median age 51 years
(range 68-21); PS 0 in 13 pts; I in 37 pts, and 2 in 5 pts. Patients were
stratified according to previous treatment as follows: group 1 relapse,
less than 4 months from last treatment, group 2 relapse 4-12 months
from last treatment. The treatment consisted of continuous
intravenous infusional 5-fluorouracil (5FU) 200 mg/m2 per day via a
Hickman line and ambulatory pump. In addition patients were given
3-weekly boluses ofcisplatin 60 mg/m2 iv and epirubicin 50 mg/m2 iv
for a maximum of 18 weeks (6 cycles). There were 8 complete
remissions (CR) and 15 partial remissions (PR) with a median
duration of response of 7+ months (range 2+ to 18+ months). The
overall response rate was 23/55 (42%); 10/35 (29%) group 1, 13/20
(65%) group 2. The treatment was well tolerated in the majority of
patients. ECF is a very active regimen in patients with EOC relapsing
from platinum-based ormultiple priorchemotherapy regimens.
050 A RANDOMISED TRIAL OF DOSE INTENSITY IN
ADVANCED EPITHELIAL OVARIAN CANCER (EOC).
P.N. Mainwaring*, R.P. A'Hern, V. Macfarlane, M. Slevin,
P. Harper, R. Osborne, M. Quigley, A. Jones, J. Mansi; P. Blake, E. Wiltshaw,
M.E. Gore for the London Gynaecological Oncology Group
There have been 9 randomised trials of platinum dose intensity in
advanced EOC. Two of the smaller trials have suggested a benefit but
all of the previous studies have used platinum in combination with
other drugs. Two hundred and forty patients with advanced EOC were
randomised to receive single agent carboplatin, dosed according to the
Calvert formula, either at a standard AUC 6 for 6 cycles or at an AUC
of 12 for 4 cycles, in both arms of the study the treatment cycle was 28
days. The median total dose received was 3,580 mg (700 - 5,640) and
4,311 mg (0 - 7,490) for the standard and higher dose arms
respectively, representing a 20% percent increase in received total dose.
Dose modifications were introduced if patients experienced prolonged
platelet and/or neutrophil myelosuppression or significant falls in 5'Cr-
EDTA clearance. Haematological toxicity was assessed by full blood
counts prior to each cycle and on day 14 in patients receiving the higher
dose treatment. 5'Cr-EDTA clearance was performed prior to each
course oftherapy for patients receiving carboplatin AUC12 and prior to
courses 1 and 4 for those treated in the standard dose arm. 122 patients
had measurable disease and 35 had evaluable disease only. There were
no significant differences in response rates between the two patient
groups; AUC6 64% (32%CR) and AUC12 55% (32%CR). There was
no significant difference in progression-free or overall survival between
the two treatment arms. Median progression-free and overall survival
were 12 and 29 months (AUC6) and 11 and 36 months (AUC12)
respectively. Dose reductions were made in 3% (3/117) and 26%
(27/109) of patients receiving carboplatin AUC6 and AUC12,
respectively. Significantly more infections (p = 0.003), diarrhoea (p =
0.07) and alopecia (p = 0.02) occurred in the carboplatin AUC12 arm.
We have not shown a survival benefit for increasing the received total
dose ofcarboplatin by 20%.
052 THE G-CAT REGIMEN: PLATINUM, TAXANE, &
ANTHRACYCLINE FOR ADVANCED OVARIAN
CANCER. M.E. Hill, R.K. Gregory, J. Moore, S.R.D.
Johnston, P. Blake, J. Shephard, D. Barton, M.E. Gore. Gynaecology
Oncology Unit, Royal MarsdenNHS Trust, London, SW3 6JJ.
A recent meta-analysis has suggested that addition of an anthracycline to
platinum-based chemotherapy may improve survival in advanced ovarian
cancer. In GOG trial 111, cisplatin/paclitaxel appeared superior to
cisplatin/cyclophosphamide. It is thus logical to investigate the feasibility
of a platinum/anthracycline/taxane combination in this disease, both as a
definitive therapy or prior to further intervention (e.g. interval debulking
surgery, high dose chemotherapy etc.). G-CAT is one such regimen, and
consists ofdoxorubicin (dox) 50mg/M2 or epirubicin (epi) 60 mg/m2 bolus,
paclitaxel (tax) 175mg/M2 over 3 hours and either cisplatin (cis) 75mg/m2or
carboplatin (carbo) AUC 7, with G-CSF at the neutrophil nadir. 26
patients have been treated in a phase I/II study which has toxicity as the
main endpoint. 8 patients received dox/tax/carbo, 8 dox/tax/cis and 10
epi/tax/carbo. Treatment was given 3-4 weekly and toxicity assessed
according to CTC criteria. Median age was 49 (range 27-67). 13 patients
had epithelial ovarian cancer (all ineligible for national trials) and 13
gynaecological carcinomas therapeutically similar to ovarian cancer
(peritoneal, fallopian tube, mixed Mullerian). 134 cycles of chemotherapy
have been given, with a median of6 per patient (range 2-6). 69% ofpatients
required at least one dose reduction. 19 patients experienced grade 34
neutropenia (8/8 with cis) and 11 grade 3-4 thrombocytopenia (10/18 with
carbo). There were 6 grade 3/4 infections and no toxic deaths. Non-
haematological toxicities were manageable, with the exception of lethargy
which occurred in 75% ofcis treated patients. Grade 1/2 cardiotoxicity as
assessed by pre- and post-treatment left ventricular ejection fraction was
observed in 5/13 patients who had received dox (results from epi treated
patients will be presented). There was no grade 3/4 cardiac toxicity or
clinically evident cardiac dysfunction. The response rate in 20 evaluable
patients was 95% (12 CR, 7 PR). We conclude that G-CAT shows high
activity and can be administered safely. Only very fit patients are suitable
as the regimen is associated with considerable toxicity, but of the 3
combinations tested, epi/tax/carbo was the best tolerated.30 Oral Presentations
053 ARANDOMISEDTRIALCOMPARINGECFWITH
FAMTIX IN ADVANCED OESOPHAGOCGASTRIC
CANCER - UPDATED 2 YEAR FOLLOW-UP. Webb A, Cunningham
D',S eJH2, HaperP, Norman A',JoffeeJK4, Hughes M5,MansiJ6, Findlay
MI, Hill A. TheRoyal Masden Hospital, Suttorn, Suney'. Chrisie Hospital,
Manchester2. Guys Hospital, London3, St James Hospital, Leeds4. Beatson,
Glasgow5. StGeorgesHospital,London6, UK.
Aim. To evaluate a pr cvely randomizedstudycomparing ECF (epirubicin
(50mg/rn), ciplatin (60mg/m), protracted venous iiusion 5-fluorourail (200
mglm2/ day)] with the stardanr combination of 5-fluorouracil, aiamycin and
mthotrexate (PAMTX) in previously unteated patients with advanced
oesophagogastriccacer.
Methods: 274 patients with adenocarcinoma/undfferniated crcinoma were
randomized, andanalyzed forsurvival, tumour response, tocity, qualiy oflife
(QL)andcostanalys
e : Overal responseratewas 46% inECFand21%inFAMTX(P=0.00003).
Toxicity was tolerable and ther wem only 3 toxic deaths. FAvfTX regme
caused morehaematolog-,al toxicity and serious infections but ECFcmsedmore
mesisandalopecia. The medians vival was8.6months inECFand6.0mornths
in FAMTX (P=0.001). ForECF, 1 and2 yearsurvivals were36.9%,12.9% and
for FAMTX 21.50%, 5.5% repecively with 92% ofpaties deal Them dian
failure freesurvival was 7.3 monthsin ECF and 3.2 monthsin FAMTX
(P<0.0C01). Theglobal QL scores were better for ECF at 24 weeks but the
remaining QL data showed no differences between either arm of thetudy.
Hospital based cost analysis on a subst ofpatients was inilar for each arm and
translted in toanincremental costof750 per lifeyearinLd.
CondusionsThe ECF regimen reslts in a survival and response advatage,
tolerable toxicity, beter QL and cost effectiveness when compared to FAMTX
chemotherapy. This regimen should now be considered the tandar treamnit
foradvancedoesophagostriccancer.
055 Is SMALL BOWEL IMAGING USEFUL WHEN PLANNING
PRE-OPERATIVE RADIOTHERAPY FOR RECTAL
CANCER? M Collinson, A Crellin, S Edwards,J Campbell, D
Sebag-Montefiore. Yorkshire Centre for Cancer Treatment, Cookridge Hospital,
Lecds.
Introduction. The small bowel is the normal tissue responsible for a significant
proportion ofthe acute and late morbidityofpelvic radiotherapy. Pre-operative
radiotherapy for locally advanced rectal cancer has used either parallel opposed
techniques las in the MRC CR02 trial] or planned volumes. This study quantifies the
small bowel volumeISBV] using both techniques.
Methods. Twenty patients with rectal cancer who were planned to receive pre-
operative radiotherapy were studied. Patients were given 300mls ofBaritop 100 and
20m1s ofGastrograffin orally 45 to 60 minutes prior to simulation. Radiotherapy
fields were as follows:- superior border 5 cm above tumour or S2/3 junction
[whichever was more superior], inferior border_5 cm below the tumour, lateral
borders_ 3 cm lateral to tumour, posterior border the whole thickness ofsacrum at
level ofthe tumour, anterior border_3 cm anterior to tumour or anterior rectal wall
Iwhichever was the moreanterior]. The SBVs were calculated using the method of
Gallagher et al [II for both a two field technique and a planned volume.
Results. The median planning target volume was 1896 cm3 [range 998-4520 cm3J.
The median SBV was 5 cm3 [rangc 0 to 1103 cm3] with a planned technique and
49.8 cm3 Irange 0 to 1239cm3J using a two field technique. Ten patients 150%I with
a planned technique and five patients [25%J with the two field technique had no small
bowel in the treatment volume.
Conclusions. This study demonstrates that the use ofplanned volumes allowed the
complete exclusion ofsmall bowel from the treatment volume in ten patients,
compared with five patients using a two field technique. The four patients with an
SBV of > 0(t) cm3 could not be predicted on the basis ofthe either the size or
position ofthe radiotherapy volume borders. Small bowel imaging is a simple
technique and mayallow a reduction in the treated SBV in a minority ofpatients by
the use of shielding techniques.
References.
Ill Gallagher MJ, Brereton HD, Rostock RA, Zero IM, Zekoski DA, Poyss LF,
Richtcr MP, Kligerman MM. A prospective studyoftreatment techniques to
minimizcthe volume ofpelvic small bowel with reduction ofacute and late effects
associated with pelvic radiation. Int.J. Radiat. Oncol. Biol.Phys. 12: 1565-1573, 1986.
054 TELOMERASE ACTIVATION IS AN EARLY
FEATURE OF COLORECTAL NEOPLASIA
S. 0 Odogwu,1. A Fraser & A.G Morris, Dept. of Surgery, Walsgrave
Hospital, Coventry & Dept. ofBiological sciences, Warwick University
9ackground: Telomerase is an enzyme which has been identified ingerm
cells and several tumours. It is not expressed by normal somatic
tissues.Telomerase expression enables cells to divide indefinitely and
renders them immortal.This immortalization may be an important stepin
the malignant proc,ss.
Aims To determine the incidence of telomerase expression in colorectal
cancersand adenomatous polyps and to identify the stage at which the
enzymeisfirst activatedWe also analyzed the degree of telomerase
activity in polyps and correlated this to the degree ofdysplasia.
Methods: Telomerase activity was detected using the Telomeric Repeat
Amplification Protocol (TRAP assay).This is a highly sensitive
Polymerase Chain Reaction (PCR) based technique.PCR products were
resolved by gel electrophoresis,autoradiographed and analyzed by
densitometiy.
Results: 48 out of 50 (96%) carcers were found to be positive for
telomerase.These ranged from Duke's A lesions to metastatic tumours. 50
correspondingsamples ofnormal mucosa were negative
5outor 35 (14%) polyps were found to be telomerase positive. All 5 were
villous adenomas.The degree of activity increases with degree of
dysplasia.
Conclusions:Telomerase is expressed early in the malignant process in
colorectal cancer.Enzyme activation appears to occur at the dysplastic
polyp stage.It is very tumour specific anid no significant activity was
detected in any ofthe nornal samples analyzed. In the future, telomerase
may be a usefulmarker for early diagnosis or follow up of malignant
disease. It is also a potential target fur drug therapy.
056 RADIOTHERAPY(RT) VS RADIOTHERAPY +
CHEMOTHERAPY(CT) AS ADJUVANT THERAPY
FOR RECTAL CANCER : PRELIMINARY
ANALYSIS OF PELVIC TOXICITY IN QUASAR
Roger James and Pat Price
On behalfoftheQUASAR steering committee
Objectives: Adjuvant RT reduces the risk of local recurrence in
operable rectal cancer. Adjuvant CT may improve survival in colorectal
cancer. This study investigates whether the regimen of pelvic RT with
concomitant adjuvant CT (CRT) produces unacceptable acute toxicity.
Methods: Patients (pts) scheduled for post-operative pelvic RT and
randomised to the uncertain arm of QUASAR (5FU/high or low dose
folinic acid/± Levamisole) or no CT were studied. Dose and schedule
modifications were recommended within the protoeol: (i)5FU 20% dose
reduction once weekly (300mg/M2 wks 1-5 of therapy) (ii) pelvic RT
.1.8 Gy per fraction (#). Acute pelvic toxicity was recorded & graded
retrospectively from a questionnaire sent to clinicians (Grade I-IV CTC
classification).
Result: Data were requested on all uncertain indication patients scheduled
for post-operative RT between 4.94 & 10.96. 74 questionnaires were
retumed, 64 containing invaluable information (34 RT, 30 CRT). Pt age
& sex were matched in both groups (median age 64 yrs; range 30-76 yrs,
31% female, 69% male), as were total RT dose, number of # & RT
duration. The dose per # was higher in the RT arm (median 2.0 vs. 1.8,
Mann Whitney p=0.002). Commonest RT schedules used were: 45 Gy/25
# (31%), 45 Gy/20 # (23%), 50.4 Gy/28 # (14%), 50 Gy/25 # (12%), 40
Gy/20 # (11%). No pt received pre-operative RT. Overall 44% reported
pelvic (gastrointestinal and genitourinary) toxicity including 40% who
developed diarrhoea, predominantly Grade II. Grade IV bowel toxicity occurred in 2 patients (both CRT). Pelvic toxicity was significantly more
frequent in the CRT group (62% vs.29%)p=0.014. This toxicity did not
correlate withpts' age, dose/#, number of # nor RT duration.
Conclusion: This preliminary analysis confirms that CT combined with
RT produces more pelvic toxicity than RT alone. Pelvic CRT should be
approached with cmution. The dose modifications recommended in the
QUASAR study appear reasonable. Pre-operative pelvic RT may be the
preferred option when adjuvant CT is to be considered. A full qualitv of
life study within QUASAR is ongoing.Oral Presentations 31
057 CHEMORADIOTHERAPY FOR RECTAL CANCER
-HIGH COMPLIANCE, LOW TOXICITY AND
EARLY RESULTS. D. Sebag-Montefiore', RGlynne-
Jones2; Cookridge Hospital, Leeds', Mount Vemon Hospital, Northwood2.
Introduction Concurrent chemo-radiotherapy (CRT) in rectal cancer has
been reported to result in high response rates although concerns remain over
radiotherapycompliance and acutetoxicity. The initial results using the same
CRTprotocol bytwo clinical oncologists in two centres is reported.
Methods 50 consecutive patients with rectal cancer have received CRT.
Group 1:-CRT alone for 10 patients (6 mobile, 2 tethered,2 fixed) with a
median age of 82 (range 75-92). Group 2:- pre-operative adjuvant CRT for
36 patients (22 fixed,10 tethered,4 bulky mobile) and Group 3 -CRT for
local recurrence for 6 patients. Radiotherapy - 3/4 field plan (45 Gy in 25
fractions). Chemotherapy - folinic acid 20mg/m2 i/v bolus followed by 5
Fluorouracil 350mg/m2 as a 30-60 minute infusion on days 1-5 and 29-33.
Patients in group 2 were considered for resection 4-6 weeks after completion
ofCRT. 7patients in group 1 received a brachy-therapy boost.
Results Ofthe 44 patients evaluable for compliance, 40 (91%) received
45Gywithout a break, 3 patients (7%) received the full dose with a rest of3-7
days and 1 patient (2%) received a total dose of43.2Gy. 3/44 (7%) patients
experienced WHO grade 3 toxicity (1 nausea, 1 diarrhoea, 1 urinary) and
there was no Grade 4/5 toxicity. Group 1:- O£the 9 patients evaluable for
response, 5 patients achieved clinical complete response (CCR) and 4 patients
clinical partial response (PCR). Group2:- Of30 evaluable patients for
compliance, 29(97%) 45Gy without a break and 1 patient required a rest
from treatment of7 days. All 30 patients receivedthe full planned doses of
chemotherapy. WHO grade 3 toxicity was seen in 2 (6%) patients (1 urinary
and I diarrhoea). To date, 26 patients have undergone resection and was
considered curative in 21 (81%). Histo-pathology is available for 21 patients:-
path CR-2 (9%), Dukes A-4 (19%), Dukes B-10 (48%), Dukes C-5(24%).
Group3:- Of4 evaluable patients,1 patient experienced WHO grade 3 nausea.
1 patient had CCR, 2 patients have had resections, 1 ofwhom had path CR.
Conclusions CRT usingthe above regimen is associated with high
complimnce and acceptabletoxicity. The early results demonstrate a high
response rate in group 1 andthehistopathological outcome forgroup 2
patients (9%pathological CR and 19% Dukes A) are encouraging.
059
FOLLOW-UP OF PATIENTS WITH METASTATIC LIVER
LESIONS TREATED WITH INTERSTITIAL LASER THERAPY
A R Gillams, J Brookes, C Hare, S Bown,* I Taylor,+ J Ledermann++
and WR Lees. The Departments ofMedical Imaging, Surgery,
Medical Oncology++ and The National Laser Centre*, The Middlesex
Hospital, London, UK.
Object: To determine outcome for patients enrolled in the liver
tumour laser programme. Methods: The study group comprised 55
patients (37M:18F, mean age 56y (31-80) who were treated with
interstitial laser therapy (ILT). The majority of patients had primary
colorectal carcinoma. Patients were usually referred for ILT when other
treatment options had been exhausted. Fourteen patients (25%) had
had prior liver resection for metastases, 48 (87%) had received systemic
(5 Flouracil and folinic acid) or intra-arterial chemotherapy at some
stage, 36 prior to ILT, 10 concurrent and 2 post ILT. At the time of
ILT mean lesion number was 2.7 (1-12) and mean lesion size 2.7cm (1-
6cm). Results: Long term follow-up data was available in 44. Mean
number of laser treatments was 2.2 (1-5). Mean length of survival
from resection ofthe primary lesion was a minimum of27.6 months (4-
86). Mean length offollow-up from first detected liver metastasis was
18 months (3-47). Mean length of follow-up in the laser programme
10 months (2-41). One year survival was 87%. Reasons for treatment
failure were the development of metastases elsewhere (n = 15), hepatic
recurrence or new hepatic metastases (n =21). Eight patients continue
in the laser programme. Up-to-date survival figures will be presented.
Conclusion: An aggressive, multi-disciplinary approach to patients
with limited liver metastases (<5 in number, <5cm diameter) is
warranted in terms ofimproved survival.
058 PREOPERATIVE CHEMORADIOTHERAPY FOR
RECTAL CANCER: PRELIMINARY RESULTS OF
ASSESSMENT BY PET SCANNING. S. Beesley, L. Biassoni, M.
Maisey and M. Leslie. Depts of Clinical Oncology and Clinical
PET, St Thomas' Hospital, London, UK.
The results of treatment for fixed/tethered
rectal tumours can be improved by pre-operative
chemoradiotherapy. Tumour response assessed
clinically or by conventional imaging studies can
only be determined some weeks after the
completion of treatment. We have investigated
whether PET scanning using FDG will allow an
early assessment of response to treatment. So
far 9 patients have been studied with serial PET
scans before, during and after treatment. Our
initial studies demonstrate that the tumours are
well visualised with PET and that marked
reductions in FDG uptake are seen once
chemoradiotherapy is commenced. If PET
scanning can predict for tumour response to
chemoradiotherapy at an early stage in
treatment it will allow for greater confidence
in the use of the neo-adjuvant approach which
will be of relevance to the treatment of tumours
at a number of different sites.
060 MATURE DATA FROM A LARGE RANDOMISED TRIAL
OF 'TOMUDEX' V 5-FLUOROURACIL PLUS FOLINIC
ACID (MACHOVER REGIMEN) IN ADVANCEI COLO,RECTAL CANCER. D.qunninghar D.Kerr12 P.Woll,'H.Anderson, J.WzAleer, P.Harper, F.Smith, N.Minton.
'Tomudex' Study Group, Zeneca Pharmaceuticals, Macclesfield
We report mature data (minimum follow up 9 months) from a
randomised, open trial comparing the direct and specific thymidylate
synthase inhibitor 'Tomudex' (raltitrexed, Zeneca) 3mg m-2 iv over
15 min once every 3 weeks (n=247) with 5-FU 400mg m-2 + FA
200mg m-2 iv for 5 consecutive days every 4 weeks (n=248).
The median duration of treatment was 12.7 weeks (range 3-58) for
'Tomudex' and 16.9 weeks (range 4-60) for 5-FU + FA. Overall
objective response was similar for both treatments (19% for
'Tomudex' and 18% for 5-FU + FA; odds ratio: 'Tomudex' 5-FU +
FA = 1.03; 95% CI 0.65 to 1.63, p = 0.90) as was median survival
(10.7m for 'Tomudex' and 11.8m for 5-FU+FA; hazard ratio = 1.13;
95% CI 0.87 to 1.45, p = 0.36).
There was a statistically significantly lower incidence ofWHO grade
3+4 mucositis (2% v 16%) and a lower incidence ofleucopenia (6%
v 13%) and diarrhoea (10% v 19%) on 'Tomudex' compared with 5-
FU + FA and a statistically significantly higher incidence of
asymptomatic, reversible, grade 3+4 elevations in hepatic
transaminases (13% v 0%). 71% ofpatients on 'Tomudex' and 48%
ofthose on 5-FU + FA received treatment without dose reduction or
delay. Palliative benefits were seen for both treatments in terms of
disease related symptoms and an improvement in performance status
(38% of patients on 'Tomudex' and 31% on 5-FU + FA improved
performance status relative to entry).
In conclusion, this mature data indicates that 'Tomudex' has similar
activity to high dose 5-FU + FA (Machover regimen), with an
acceptable safety profile and more convenient 3-weekly dosing
schedule and reinforces the advantages ofpalliative chemotherapy for
advanced colorectal cancer.32 Oral Presentations
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A PROSPECTIVE RANDOMISED TRIAL OF
PROTRACTED VENOUS INFUSION(PVI) 5-
FU WITH OR WITHOUT MITOMYCIN C
(MMC) IN ADVANCED COLORECTAL CANCER. P Ross, A
Norman, D Cunningham, A Webb, T Iveson, A Padhani, and A
Massey. The Department of Medicine and The Gastrointestinal Unit,
The Royal Marsden Hospital, London and Surrey, SM2 5PT.
Aims To compare PVI 5-FU with or without MMC for tumour
response, survival, toxicity and quality of iife (QL) in patients with
previously untreated advanced colorectal cancer.
Methods 200 patients received PVI 5-FU (300mg/mi2/day for 24
weeks) with or without MMC (10mg/m2 IV bolus 6 weekly for 4
courses; 7mg/mi2 from June 1995).
Results Overall response was 54% (95% confidence intervals [CI]
44.1-63.9%) with PVI 5-FU+MMC compared to 38% (CI 28.3-47.7%)
with PVI 5-FU alone (p=0.024). PVI 5-FU+MMC caused more overall
haematological toxicity but CTC grades 3/4 was increased only for
thrombocytopenia (p=0.0006). Two patients treated with a cumulative
MMC dose of 40 mg/m2 developed haemolytic uraemic syndrome
(HUS) warranting a reduction in cumulative MMC dose to 28mg/mi.
2 No HUS developed inpatients treated with MMC to 28mg/m . Median
failure free survival was 7.9 months with PVI 5-FU+MMC compared
to 5.4 months with PVI 5-FU alone (p=0.033) with 31.9% and 17.7%
respectively alive and failure free at year. Median overall survival
was 14 months with PVI 5-FU+MMC compared to 15 months with PVI
5-FU alone with year survival of 51.7% compared to 57.2%. Global
QL scores were better for PVI 5-FU+MMC
Conclusions PVI 5-FU+MMC results in improved response and failure
free survival, tolerable toxicity and better QL when compared to PVI 5-
FU alone. There is no irreversible toxicity with MMC at a cumulative
2 dose of 28mg/m This regimen is suitable for evaluation as adjuvant
therapy in colorectal cancer.
063 ALTERNATING ChlVPP/PABIOE IS
BETTERTHAN PABIOEALONEAS
INITIAL CHEMOTHERAPY FOR
ADVANCED HODGKIN'S DISEASE: FIRST RESULTS OF A
BNLI/CLG STUDY. B W Hancock', M H Cullen2, G Vaughan
Hudson3,'YCRC Dept. of Clinical Oncology, Weston Park Hospital,
Sheffield, 2CRC Trials Unit, Queen Elizabeth Hospital, Birmingham,
3BNLI, The Middlesex Hospital, London.
This British National Lymphoma Investigation (BNLI)/Central
Lymphoma Group (CLG) trial commenced in October 1992 and was
prematurely concluded in April 1996 afte. the first interim analysis.
682 patients (461 BNLI, 221 CLG) were randomised to either
ChlVPP/PABIOE (chlorambucil, Velbe, procarbazine, prednisolone
alternating with prednisolone, Adriamycin, bleomycin, Oncovin and
etoposide) or PABIOE alone. 604 patients are so far evaluable for
response and survival analysis. The patient characteristics were
balanced between the two treatment arms. In the ChlVPP/PABlOE arm
the complete remission and freedom from progression rates are
significantly higher (75% vs 60% and 72% vs 52% at 2 years,
respectively). At present there is no significant difference in the overall
survival between the two arms. There was significantly more grade
III, IV toxicity for myelosuppression and infection in the
ChlVPP/PABIOE arm. ChlVPP/PABIOE will be a 'standard' therapy
in the next United Kingdom Lymphoma Group randomised study in
advanced Hodgkin's Disease.
062 RADIOTHERAPY IN THE TREATMENT OF
ELDERLY PATIENTS WITH HIGH OR
INTERMEDIATE GRADE NHL, J.P.Wylie, R.A.Cowan, Dept.
OfRadiotherapy, Christie Hospital, Manchester M20 4BX...
The treatment ofelderly patients with high or intermediate grade
NHL remains difficult and controversial. 270 elderly patients
treated between 1987-1992 with such a diagnosis were
retrospectively reviewed. Eighty one, unfit for chemotherapy,
received fractionated radiotherapy for apparently localised stage
I or II disease. 25% were considered adequately staged. The
pathology was reviewed in 77% ofcases.
Median age was 78 years (range 70-87). Forty stage I and
seventeen stage II patients had extra-nodal sites ofdisease. Nine
had bulk disease and five B symptoms.
The radiation field included the primary site plus immediate
adjacent nodes. After a median follow-up of3.9 years the 5 year
OS and DFS was 28% (CR 72%) and 21% respectively. Age
(p=0.003), stage (p=0.004) and lactate dehydrogenase level
(LDH) (p=0.006) were identified as independent risk factors for
recurrence. These factors can define a group in which
radiotherapy can produce acceptable survival rates.
These patients (age < 80 years, stage I, LDH <500) had a 5 year
DFS and overall survival of56% and 62% respectively.
Using modem day prognostic factors it is possible to define a
proportion of elderly patients, unfit for chemotherapy, who can
derive acceptable relapse-free and survival rates from
radiotherapy alone.
064
POST-TREATMENT REMISSION ASSESSMENT IN LYMPHOMA
USING FDG-PET SCANNING, N.G. Mikhal', V. Ahem', S. Barrington2,
A.R. Timothyl, DeparnMent ofClinical Oncologyl and Clinical PET Centre2,
Guy's and St Thomas' Hospital, Lambeth Palace Road, London SEI 7EH,
UJK.
Although CT scanning is now the most widely used imaging technique in
lymphomas, the information obtained from CT scans in the post-treatment
setting is limited by the minimum volume ofdisease that can be detected and
the inabilitytoassess diseaseactivity in residual abnormalities.
2-(Fluoro-18)-fluoro-2-deoxy-D-glucose (FDG) has been consistently shown
to concentrate preferentially in metabolically active tissue including
lymphoma. As part of an ongoing protocol to improve the accuracy of
pretment staging and remission assessment for malignant lymphomas, we
have been using FDG whole body Positron Emission Tomography (PET)
scans inconjunction with CT scanning.
Fifty lymphoma patients have undergone FDG PET scanning fbr post-
treatment remission assessment. Ten patients had residual activity on post-
treatment PET scans but only 5 had residual abnormalities on CT with PET
scans consistently showing more sites ofinvolvement. Ofthe 10 PET scan-
positive patients, 9 had persistent disease or relapsed later at sites ofresidual
activity (ie. true positive PET). One patient had a negative biopsy of the
mediastinum despite both abnormal PET & CT scans but the dumion of
follow-up on this patient is still short. Forty patients had normal post-
treatment PET scans although CT scan showed residual abnormalities in 14
patients. No relapse inCT-positive sites has occured intesepatients to date.
Our preliminary experience suggests that FDG PET scanning offers a highly
sensitive method of assessing remission status fbliowing treaunent of
lymphom.Oral Presentations 33
O065; FIRSTDEMONSTRATIONOFANTI-LYMPHOMA ACTIVITYOFBCL-2ANISENSEMOLECULE-
G3139;RESULTSOFPHASE1/IACLICALTRIAL.AWebpl,D
Cumnigham, FConter?,PRoss',JWalters,IJudson,
I FRad,PClarke,
ZEDXiewarsowsa,RoyalMrsdenHospital'(RMH),UK,InstituteofChild
Health,UK,Gentalnc,US.
intrductn: It has been well known that T14/18 trnslocation in follicular
lymphoma up-regulates BCL-2, leadig to continued expression of BCL-2
protein. Uprgulation of BCL-2 leads to extended survival of the cells and
increased chemoresistance. Clinical tials demonstated correlation between
BCL-2 expressionandpoorclinicalprognosis in anintermediateandhighgrade
lymphomas. G3139 is anall-phosphorothioate 18meroligonucleotidestargeted
to the first six codons ofthe BCL-2 mRNA. It has been shown to specifically
down rgulate BCL-2 in vitro and to have dose d qepedet activity in mice
modelsofhuma lymphomaaswellasotherxenogmftmodelsofsolidtumours.
MeUiods:TheLymphomaUnitattheRMHperformedthefirstPhaseItrialinall
grades NHL pts who relapsed following several previous conventional
chemoteapy regimens and who exrssed BCL-2. Replicating preclinical
xenograft model, thepatientsreceivedG3139 as acontinuous, subcutaneous 14
day infusion. Thedoses wereescalatedaccording to EORTC schemeandsafety
aswellasefficacymeasuredusingstlandevaluationcriteria
Results: Until early Febnuary1997> 13 pts were entered in 6 dose escalation
cohortsupto adoseof147.2mg//day. Basedonexcellentsystemictolerance
theescalations weremadein 1000/%increments. Atthe6thdoselevel,reversible
grade 3 thrombocytopenia was observed in 1 pt Mild topical, infusion site
irritationwhichwasgenerallyacceptablebuttwoptshad more severereversible
reations which were not dose dependent Blood levels of two pts at 5th
escalation level approximated concentration effective in in vivo models of
lymphoma Inthefirst9pts,4ptsdemonstratedimprovementindiseasestatusas
defined by clinical andror laboratory parameters incluing decrase in BCL-2
protein. One of those 4 pts demonstated minor tumour response. Another
patient on the higher dose, who failed 4 priortapies, with folliculargrade II
lymphoma, stageIVB,developedcompleteclinical andradiological respohseof
30+weekduration.
Conclusion: We conclude that antisense approach to BCL-2 constitutes a
potentially important treatnentmodality inNHL, leading to responses in poor
prognosis patients atdoses causing lowtoxicity. Thetrial is continuing andthe
fullupdatewllbepresentedc
067 TREATMENT OF PERIPHERAL BLOOD
PROGENITOR (PBPC) HARVESTS BY TWO-
STAGE IMMUNOMAGNETIC SELECTION:
YIELDS COMPARABLE TO POSITIVE
SELECTION ALONE.
P.W.M. Johnson', R. Coupe2, D. Clarke', A. Lubenko2, K. Short',
T.J. Perren', P.J. Selby', S. MacLennan2. 'ICRF Cancer Meuiicine
Research Unit, St James's Hospital and 2National Blood Service
Yorkshire, Leeds.
Purpose: To determine the feasibility of sequential positive and negative
selection to enrich haemopoietic progenitors and deplete tumour cells
from PBPC's for rescue following high-dosechemotherapy.
Methods: Aliquots of 9 PBPC harvests (0.59-2.3 x 101" cells) were
processed by immunomagnetic selection using antibodies (Ab's) to
CD34 for enrichment of haemopoietic precursors, followed by
depletion of tumourcells using acocktail of Ab's to either 5 lymphoid
or 3 epithelial antigens for lymphoma (5 pts) or breast cancer (4 pts)
respectively. Separations were carried out using paramagnetic beads
and a magnetic column, with removal of beads after the positive
selection by competitive release. Numbers of CD34+ cells were
measured by flow cytometry and CFU-GM enumeratedin the apheresis
product and ateach stage of the procedure.
Results: The initial meanconcentration of CD34+ cells was 1.73% (+/-
0.81), increased to 90.8 % (+/-8.25) following enrichment and 92.6%
(+/-7.05) after both stages. CFU-GM were enriched a mean 203-fold
(+/-164) after enrichment and 241-fold (+/-132) in the final product.
For the enrichmentstep the meanyield of CD34+ cells was 34.5% (+/-
11.8), and for depletion 92.1%(+/-6.7). Overall the mean yield of
CD34+ cells was 33.6% (+/-9.15). By projecting the numbers of
CD34+ cells from the total harvest on 2 days apheresis, all 5 patients
with lymphoma and 1 patient with breast cancer would have had
sufficientnumbers (>2 x 106/kg) for rescue following both stages. The
proportion of CD34+ cells in the apheresis product was a good
predictorof adequatenumbers ofcells remaining after processing, with
acut-off at 1%.
Conclusion: Two-stage selection of PBPC gives yields of early progenitors very similar tosinglestage enrichment, suggesting that this
is a feasible method for in vitro treatment to remove tumour cells,
provided the harvestcontains at least 1% CD34+cells.
066 ESTABLISHING A REGIONAL BLOOD STEM CELL PHERESIS SERVICE: THE
NORTH TRENT EXPERIENCE. PC Lorigan*l
and DA Jones2. 1YCRC Dept of Clinical Oncology, Weston Park
Hospital, Sheffield S10 2SJ, 2National Blood Transfusion Service,
Longley Lane, Sheffield S5 7JN.
In 1994, a regional blood stem cell pheresis service was
established as a joint venture between Blood Transfusion Service
(BTS) and Weston Park Hospital (WPH). The service is
administered by BTS which also provides the nursing and technical
expertise needed for the procedure and processing of the product.
The facility is based at WPH which provides nursing back up.
Medical expertise is provided by both centres.
162 patients have been referred for stem cell harvesting to date.
These comprised non-Hodgkin's lymphoma (22.8%), relapsed
Hodgkin's Disease (17.9%), multiple myeloma (11.7%), breast
cancer (7.4%), and a mixture of acute leukaemia, Ewing's sarcoma,
relapsed germ cell tumours, healthy donors, paediatric malignancies
and others. 95% of cases were referred by the three centres
providing Medical Oncology, Haemato-Oncology and Paediatric
Oncology. Priming regimens were standardised, the majority of
patients received cyclophosphamide 3g/m2 and GCSF but a number
of other regimens were also used. The decision to harvest was
based on the peripheral CD34 positive cell count which was shown
to correlate with the total yield (Lorigan et al. BJC 1996, 73, Suppl.
XXVI, 235). 134 patients have undergone blood stem cell
harvesting. The remaining patients were not harvested because ofa
low peripheral blood CD34 positive cell count, infection or disease
progression. Patients had a mean of 2 harvests. The total CD34
positive cell yield was <1.0 x 106/kg in 19% of patients, between
1.0 and 1.9x106/kg in 20% and >2x106/kg in the remaining 61%.
Factors which predicted poor mobilisation have been identified.
A regional blood stem cell pheresis service offers centralisation
of expertise, economies of scale and the opportunity to standardise
management of this heterogeneous group ofpatients.
068 STEM CELL FACTOR(r-metHuSCF) IN COMBINATION
WITH FILGRASTIM (r-metHuG-CSF) ENHANCES
PERIPHERAL BLOOD PROGENITOR CELL (PBPC)
MOBILISATION FOLLOWING CHEMOTHERAPY: A RANDOMISED STUDY
A. Weaver', P.J. Woll2, M. Lind3, C.Gill4, B. Jenkins4, T.M. Dexter', N.G. Testa' and D.
Crowther'. CRC Depts of Medical Oncology and Experimental Haematology- 'Christie
Hospital, Manchester, UK. 2Nottingham City Hospital, UK. 3Newcastle General
Hospital, UK. and 4Amgen Cambridge, UK.
It has previously been reported that SCF synergizes with filgrastim to enhance PBPC
yields in patients with breast cancer undergoing cytokine-only mobilisation We report
here that SCF plus filgrastim following chemotherapy also enhances PBPC mobilisation
compared with filgrastim alone. 48 chemotherapy-naive patients with FIGO stages 1c-IV
epithelial ovarian cancer were randomised to receive either SCF and filgrastim or
filgrastim alone following cyclophosphamide 3g/m2. The dose of SCF was cohort
dependent, with 12 patients in each cohort, 9 ofwhom received filgrastim (5jg/kg) plus
SCF and the remaining 3 receiving filgrastim (5jsg/kg) alone. The dose of SCF was
5,10,15, and 20jsg/kg in cohorts 1, 2, 3 and 4 respectively. Growth factors were
administered daily from day 3 post-chemotherapy until WBC was >4xI09/L, when all
patients underwent an apheresis, the product of which was divided into 4 aliquots, one
aliquot being reinfused following each subsequent dose-intensive cycle ofchemotherapy.
We have demonstrated a statistically significant increase in colony-forming cells and
CD331+ cells as the dose of SCF was increased. Likewise there was a significant
enhancement in yields ofCD34+ cells, CFU-GM, BFU-E and LTC-IC in those patients
receiving the higher doses of SCF plus filgrastim compared with those receiving
filgrastim alone. The median number of days (range) peripheral blood CD34+ cells,
CFU-GM and BFU-E remained above specified threshold values are presented below.
Cyclophosphamide 3g/m2 followed by
Number of filgrastim filgrastim filgrastim filgrastim filgrastim p-value*
days for: 5pg/kg 5pg/kg + 5Isg/kg + 5pg/kg + 5pg/kg +
I SCF 5pg/kg SCF lOpg/kg SCF 15pg/kg SCF 20pg/kg
CFU-GM 5 4 5 v 9 p<0.001
>5x103/nd (0-7) (2-5) (1-8) (5-10) (6-10)
BFU-E 5 5 6 7 9 p<0001
>5x103/1d (0-7) (2-5) (2-9) (6-10) (6-10)
CD34+ 3.5 3 ,p<0.001 >50X103/nd1 (0-5) (0-5) (0-8) (3-9) p(6-8)
*Linearregression on SCF dose across all 5 groups
The greatest number of days above threshold levels was observed for those patients
receiving SCF 20jsg/kg plus filgrastim for all parameters. This has an important clinical
implication in that the higher doses of SCF offer a greater 'window of opportunity' in
which to perform the apheresis to achieve high yields.34 Oral Presentations
069
DEVELOPING A MODEL FOR NURSE-LED CLINICS
WITHIN A RADIOTHERAPY OUTPATIENT
DEPARTMENT, D Dodwell, J Campbell, L German,
C Coyle, C Lane - Yorkshire Regional Centre for Cancer Treatment, Cookridge
Hospital, Leeds, LS16 6QB
Objective: To provide a descriptive account of the activities which take place
within a radiotherapy review clinic and to compare them with a nurse-led clinic.
Background: There are numerous initiatives to identify possibilities for the
greater involvement of non-medical practitioners in patient care. Suitably
trained nurses already form an important part of the multi-disciplinary team and
the enhancement of the role of the specialist nurse in other areas may improve
the delivery and quality of care.
Subjects: 71 adult patients receiving outpatient radiotherapy and assessed in the
traditional (doctor-held) radiotherapy review clinic and 141 patients from one
Consultant's practice receiving outpatient radiotherapy and reviewed in a nurse-
led review clinic.
Outcome measures: These included the activities in both clinics, including the
degree and number of interactions that occurred, consultation time, waiting
time, degree of involvement from other support services, reasons for doctor
contact and perceptions of patients, doctors and radiographers.
Results: Nurse consultations lasted significantly longer than those of doctor's.
Waiting time was reduced. Of 391 episodes of review, 21 contacts were made
with the doctor, predominantly because of the perceived need for a prescription.
There were a greater number of referrals and liaison with other support groups,
(88 referrals within 391 episodes within the nurse-led clinic, compared to 4
within 71 episodes for the traditional doctor-held clinic). Interactions were
divided into 6 broad categories (treatment enquiry, examining radiotherapy site,
provision of a prescription, psycho-social enquiry/support, investigation/other
procedures and information/advice giving). Significantly more interactions
occurred during nurse consultations.
Conclusion: This small sequential observational study suggests that once the
activities occurring within a traditional radiotherapy review clinic were
analyzed, specialist trained nursing staff, given appropriate medical support
when required, may undertake the tasks involved in a radiotherapy review clinic
equally (and possibly more) effectively.
071 INFORMATION RECALLED, HOSPITALANXIETY
DEPRESSION SCORES (HAD) ANDKNOWLEDCiE
OR CONSENT AMONGST PATIENTS UNDERGOING
RADIOTHERAPY (RT), A P M Lydon', C Montgomery2,
A Hong3, anid K Lloyd4, 'Department of Oncology, 2 Departmenit ofPsychiatry,
Royal Devon & Exeter Healthcare NHS Trust, Exeter,EX2 5DW.
Patieiits may complaini ofreceiving too little or occasionally too much information
about their cancer diagnosis anid treatment. Our aim was to determinie currenit
knowledge ofpatients undergoing RT, and any association with HAD scores.
75 patients were interviewed. They were questioned abotut their satisfactionwith
information given, knowledge of treatment related side etfects, consent and preferred
source ofinformation. All completed a standardised HAD score questioumaire.
51 (77%) of patients were satisfied with amount of information given. There
correlationi between high HAD scores and dissatisfactioni with insfonnation recalled
(p= 0.04). Only 56 (75%) could reinember signing a cotisent fonn,
27 believed they had consented to any treatment, surgery, chemotherapy anid
RT.
57 (76%) recalled acute side effects, considered inappropriate in 3. Only 2 klew of late
side efflects. 16 (22%) would have likedinore discussioit time 14 with their oncologist
preference to their GP, radiographer or patient with a similar illness.
This study is one of'the first to suggest that patients predisposed to anxiety and depression,
idenitified by HAD scorinig, are more likely to be dissatisfied with insfonnation give
about their disease and treatment. Many patients would value more time with their
oncologist. Late side efl'ects nieed tobi. discussed more freely and perliaps inicluded in
obtaininlg consent.
070 FRACTION OF NORMAL REMAINING LIFE: A NEW
METHOD FOR EXPRESSING SURVIVAL IN CANCER.
J S Vaidya*', *I Mittra'
*'Department ofSurgery, Tata Memorial Hospital, Bombay, 400 012, India
The plotting of conventional survival curves for cancer, using the interval between
diagnosis and date of last follow up or death to denote survival time, ignores the
patient's expected life span had the patient been healthy. In human terms, the impact
of a projected 10 year survival of a woman diagnosed to have breast cancer (for
example) would be different for a 30 year old patient as opposed to a 70 year old.
We believe that survival is better expressed as a fraction of normal remaining life
span expected at the time of diagnosis.
To illustrate this concept, we used a database of 1134 operable breast
cancer patients from Bombay who had their primary surgery performed at Tata
Memorial Hospital between 1974 and 1988. Each patient's age at diagnosis is
subtracted from the average life expectancy for that age to obtain what we call her
normal remaining life (NRL). At the time of survival analysis, the percentage of NRL
that has actually been lived by the patient was calculated and used in place of
survival time to plot actuarial survival curves which we call real life expectancy
curves. The survival curves were plotted in two different ways: by the conventional
method and the novel way which we call real life expectancy method. Both curves
were plotted using the actuarial method. For example, in India, a healthy 40 year old
woman has a normal life expectancy of 72 years and NRL of 32 years (72 minus 40).
If at 40 she were diagnosed to have breast cancer, and she lived for 10 years, her
survival is expressed as 31% of her NRL (10/32 xlOO). On the other hand, a similar
patient of breast cancer aged 60 at diagnosis would have a normal life expectancy of
75 years and NRL of 15 years. If she lives for 10 years after diagnosis, her survival
is expressed as 67% (10/15 x 100) of her NRL. To plot the Real Life Expectancy
curves, these percentage figures were used instead of actual number of years. The
mathematical procedure and statistical considerations are exactly the same as that
used for plotting conventional actuarial survival curves. Using the conventional
method, one would estimate that a woman with uninvolved nodes has a 82% chance
of living for 10 years while using the new method she would have a 81% chance of
living 1/2 of her NRL. Since the normal life expectancy of a 40 year old Indian
woman is 72 years and that of a 60 year old is 75 years, this would work out to a
81% chance of living for 16 years for a 40 year old woman and 7.5 years for a 60
year old. We could even say that a node-ve woman has a 68% chance of living her
full NRL which is equivalent of a cure. The importance of the facility to express
survival in terms of cure, especially for a disease such as cancer, is profound. We
believe that by individualising survival estimates according to age and expressing
survival in terms of cure rates, the new method that we have proposed makes
survival estimates more meaningful, relevant and human.
072 PATIENTS' EXPERIENCES OF MENOPAUSE
-LIKE SYMPTOMS FOLLOWING BREAST
CANCER TREATMENT R Adewuyi-Dalton, J Bradburn, E J Maher
and the Breast Cancer & Hormones InformationCommittee.
Objectives: This study explored womens' experiences of menopause-
like symptoms after breast cancer treatment. This study was associated
with a national R&D study ofHRT use. The aim was to assess the
impact ofsymptomsupon their lives, the support and information they
found to assist them andcurrent priorities in addressing the symptoms.
Method: 46 breast cancer support groups throughout the country
volunteered toparticipate. Focus groups were held with 6 groups to
elicit therange ofconcerns associated with menopause-like symptoms.
This data was used as the basis for aquestionnaire sent to the remaining
40 groups.
Results: All groups replied resulting in 344 evaluable questionnaires.
* Symptoms: hot flushes (80%), tiredness (74%), night sweats
(69%), weight gain (67%) and insomnia (58%). Psychological
symptoms (loss ofconcentration, memory loss, depression, mood
swings, panic attacks and loss ofcontrol) affected up to 50%.
* 62% attributed symptoms to Tamoxifen, 17% a natural menopause.
* Ofthoseexperiencing hot flushes 52% were told to expect them; for
loss ofconcentration 13%. Information sources for advice on
symptoms were diverse; 58% asked their GP, 42% a breast care
nurse, 8% agynaecologist, 36% a support group member and 33%
anoncologist. Advice was useful in understanding symptoms but
not to relieve them.
* Dealing withsymptoms: 12% considered their symptoms were of
sufficient severity to take HRT if offered. Opinion indicated that
78% wouldonly take HRT ifcancer doctors monitored closely.
Self-help strategies were prioritised by 71% and improved
information by 65%.
Conclusions: The study highlights the extent of physical and
psychological distress as a result ofmenopause-like symptoms and the
lack ofacknowledgement ofthis in terms ofthe information and
support offered. Apatient information booklet addressing this need is
currentlybeingproduced by a multi-disciplinary lay/professional group.Oral Presentations 35
073 SUCCESS AND COMPLICATIONS OF ENDOVASCULAR STENT
INSERTION IN THIENAEEU OF THE SVC (SUPERIOR
VENA CAVA) SYNDROME. S.h. Cooper, E.H. Uhitby,
P.A.Gaines, T.J.Cleveland, Sheffield Vascular Institute, Northern
General Hospital, Sheffield SS 7AU, U.K
OBJECT: To assess the success and complications of endovascular stent
insertion in the treatment of SVC syndrome in a large series of
patients.
METHODS: Of 63 patients 61 had mediastinal malignancy; 40 related to
bronchial tumours, 19 breast carcinoma, 2 other tumours. Two had benign
disease. Forty had undergone previous radiotherapy. Thirty-three
patients had total venous occlusion with 17 requiring thrombolysis or
clot aspiration prior to stenting. The reminder had uncomplicated
stenoses of the SVC or brachiocephalic veins. Twenty-one patients
required multiple stents. Forty-eight vere given Reparin during and
imediately post-procedure with 19 continuing long-ten
anticoagulation.
RESULTS: 98%. patients experienced rapid symptomatic relief. In 55
normal vessel calibre was restored, with partial recanalisation in 8.
Eight required further treatment (4 thronbolysis, 4 additional stents)
all successfully. Survival ranged frox 5 days to over 9 months, 40%
died within 1 month. Complications occurred in 8 (12.7%); 6 related to
anticoagulation (2 to thrombolysis, 2 to heparin post-procedure, 2 to
long-term anticoagulation), 1 technical failure, 1 vound cellulitis.
No deaths vere attributable to the procedure.
CONCLUSION: Stenting is a safe and effective treatment providing
almost imediate symptomatic relief. It should be available to all
patients vith the SVC syndrome.
075 WHY DO PATIENTS WITH WEIGHT'OSS
HAVE A WORSE OUTCOME WHEN
UNDERGOING CHEMOTHERAPY FOR
GASTRO-INTESTINAL MALIGNANCY?
H.J.N.Andreyev, P.J.Ross,A.R. Norman,J. Oates and
D. Cunningham GI Unit, Royal Marsden Hospital & CRC Centre of
CancerTherapeutics, Institute of Cancer Research, Sutton, Surrey.
Aims: To examine whether weight loss at presentation for
chemotherapy for gastrointestinal carcinomas influences outcome and
whether nutritional intervention could be worthwhile.
Methods: Data were gathered prospectively. The outcomes were
compared of patients with or without weight loss treated for locally
advanced or metastatic tumours of the oesophagus, stomach, pancreas,
colon or rectum.
Results: Of 1,555 consecutive patients included, weight loss was
reported more commonly by men (51%) than women (44%) at
presentation (p=0.01) Patients with weight loss received less
chemotherapy but developed more frequent and more severe dose
limiting toxicity - plantar-palmar syndrome (p<0.0001) and stomatitis
(p<0.001) - than patients without weight loss. Consequently, patients
with weight loss on average received 1 month less treatment (p<0.0001).
Weight loss correlated with shorter failure free (p<0.0001, Hazard
Ratio=1.25) and overall survival (p<0.0001, Hazard Ratio=1.63),
decreased response (p=0.006), quality of life (p<0.0001) and
performance status (p<0.0001). Patients who stopped losing weight had
better overall survival (p=0.0004). Weight loss at presentation was an
independent prognostic variable (Hazard Ratio =1.43).
Conclusions: The poorer outcome from treatment in patients with
weight loss appears to occur because they develop more toxicity, have
more breaks from treatment and receive significantly less chemotherapy
rather than any specifically reduced tumour responsiveness to treatment.
Randomised nutritional support intervention studies are urgently required
in these groups of patients.
074 PALLIATION OF MALIGNANT DYSPHAGIA
WITH EXPANDING METALLIC STENTS.
G J O'Sullivan, J L Mansi, J P Glees and A Grundy. Depts ofRadiology
& Oncology, St George's Hospital, London SW17 OQT.
Palliation ofsymptoms and complications ofstent insertion to relieve
malignant dyspagia have been retrospectively studied.
98 expanding metal stents have been inserted in 87 patients (61 male, 26
female). Age ranged from 46.2 to 92.7 years (mean 73 years). 69
patients had primary tumours ofthe oesophagus, 6 patients had recurrent
disease following previous surgery or radiotherapy and 12 patients had
extrinsic involvement by other malignant disease. 74 Strecker stents,
22 covered Wallstents, 1 Gianturco and 1 Instent were used.
Three patients died within 3 days ofstent insertion. Immediate reliefof
dysphagia was achieved in 80 ofthe remaining 84 patients. Three
fistulas to the tracheo-bronchial tree were sealed with covered stents.
There were no major complications related to stent insertion. Patient
survial ranged from 1 day to 2 years with a mean survival of7 weeks.
Major late complications were food impaction in 5 patients, stent
migration in 3, minorbleeding in 2 and the development ofan
oesophago-aortic fistula in one patient. 8 patients had tumour
overgrowth or ingrowth managed by insertion ofa second stent or laser
ablation.
Although complications may occur in about 20% ofpatients, expanding
metal stents provide good palliation ofmalignant dysphagia allowing
over 90% ofpatients to maintain oral feeding.
076 NON-SURGICAL TREATMENT FOR CHONDROSARCOMA
MQF Hatton, J Reid, S Murray*, R Reid+, A Barrett. Beatson
Oncology Centre, Westem Infirmary, Glasgow G Il 6NT.
*Dept. Orthopaedic Surgery, Westem Infirmary, Glasgow. +Scottish Bone Tumour
Registry, Dept. ofPathology, Westem Infirmary, Glasgow.
We present a retrospective review of patients with chondrosarcoma, from the
records of the Scottish Bone Tumour registry, who received radiotherapy or
chemotherapy as part oftheir treatment. There were 65 patients in this group in the
305 patients with chondrosarcoma identified in Scotland between 1960 and 1995.
Thirty five were male, the median age was 57 years (range 5 - 89).
All patients had histologically confirmed chondrosarcoma, (13 grade 1, 19
grade 2, and 27 grade 3). Forty nine patients had tumours arising in the axial
skeleton; commonest sites being pelvis (23), ribs (11), femur (9), humerus (7), spine
(6) and skull (4).
37 patients received radiotherapy as their primary treatment, a further 14 as
an adjuvant to surgery and 19 as treatment for relapse. Doses ranged from a 10 Gy
single treatment to 73 Gy in 33 fractions. One patient received primary
chemotherapy, 9 adjuvant and 15 chemotherapy for relapse.
13 patients (35%) receiving primary radiotherapy had a partial response, 22
stable disease and 2 progressed on treatment; the median time to relapse was 7
months (range 0 - 198). Palliative radiotherapy produced 1 complete and 3 partial
responses (21%), 10 patients had stable disease, 4 progressed with 1 unassessed for
response. The median time to relapse was 3 months (range 0 - 54). The median
survival for all patients following radiotherapy was 11 months (range 1 - 232).
Twenty four patients received chemotherapy, 13 were given a single agent,
11 combination treatment. Overall 3 patients had a partial responses, 8 stable
disease, 9 progressed on treatment and in 5 the response could not be assessed. The
median time to relapse was 3.5 months (range 0 - 14) and median survival following
treatment was 8 months (range I - 30).
In conclusion, this review suggests a role for radiotherapy in the palliation
of chondrosarcomas that cannot be adequately treated surgically. However, the
results seen with chemotherapy are very disappointing and the use ofthis treatment
cannot be recommended outside a trial setting.36 Oral Presentations
077 PROSPECTIVE VALIDATION OF MRC
PROGNOSTIC INDEX IN HIGH GRADE GLIOMAS.
R.Benson, S.Old. L.T.Tan, S.Harden, V.R.Bulusu, N.Burnet, Oncology Centre,
Addenbrooke's Hospital, Cambridge, U.K. CB2 20Q.
The importance ofprognostic factors in patients with high grade gliomas
has been emphasised in previous MRC studies. Age, WHO performance
status, length of history of fits and extent of surgery wete identified as
independent prognostic variables. A prognostic index was developed to
predict survival.
Aim: To prospectively evaluate the MRC prognostic index in patients
with high grade glionias.
Methods: MRC prognostic index was recorded in 62 adult patients with
high grade gliomas (WHO Gr 3&4). 54 pts received radiation, 28 had 60
Gy in 6u%ks, 14 had 45Gy in 4wks, 12 had 36Gy in 2.5wks totheir tunour
volume using 5-8Mv photons. 8 pts had biopsy only or partial excision.
Patients with MRC prognostic index of<25 received radical radiotherapy
and those witth index of >25 either had a palliative (36Gy) dose or were
treated symptomatically. All patients were followed upto relapse/death.
Three prognostic groups were createdbased on the index, Group I (n=16)
score=0-15, Group II (n=20) score=16-25 and Group III (n=26)
score=>26. Mean (95% C.I) and median survival were calculated for all
three groups.
Results: Survival data for the 3 Prognostic Groups
Group MRC prognostic Expected Observed Survival(wks)
index survival Mean Median 95%C.I.
In=16 0-15 51-80wks 147 126.5 126.5-167
II n=20 16-25 33-46wks 48.4 43.5 36.5-60
IIln=26 >25 16-28wks 17 17 13-21
Conclusions: MRC prognostic index, though a useful prognostic tool,
tends to underestimate survival in the best prognostic group (score <15),
especially in patients with scores <10. It probably overestimates survival in
the poor prognostic group (score >25).
078 ANTI-TUMOUR IMMUNE RESPONSES AFTER
MONOCLONAL ANTIBODY THERAPY OF
OVARIAN CANCER, S. Nicholson1'2, H.Thomas1, D.Snary2,J. Taylor-
Papadimitriou2. 1Dept of Clinical Oncology, Hammersmith Hospital,
London; 21mperial Cancer Research Fund, Lincoln's Inn Fields, London.
Two multi-centre trials are underway exploring the role of monoclonal
antibody HMFG1 in patients with ovarian carcinoma: patient accrual is
ongoing in a phase III trial of radiolabelled antibody and in a phase I/Il
trial of unlabelled HMFG1. The target is the tumour-associated antigen
Polymorphic Epithelial Mucin or "MUC-1."
Methods for assessing successful immune stimulation are essential, both to
understand the mechanism behind any anti-tumour effect of these
treatments, and to correlate immune response with clinical effectiveness.
The latter is important, as these approaches to treatment are most likely
to find clinical application as consolidation therapy in patients with
minimal residual disease after chemotherapy. Assays for enhanced
immune responsiveness to the target antigen have been performed.
Humoral immune responses comprise general Human Anti-Mouse
Antibodies (HAMA), and more specific anti-idiotypic (Ab2) and anti-
anti-idiotypic (Ab3) responses. The antigen binding site of Ab3 should bind
to the same epitope as the administered MAb. Assays have been
developed for measuring Ab2 and Ab3 responses in our patients. As
measured by ELISA, Ab2 signal was increased in 10/10 recipients of
adjuvant intraperitoneal radioimmunotherapy and Ab3 was increased in
6/10 patients.
Cellular responses to the antigen have been studied by measuring the
proliferation of peripheral blood lymphocytes to peptides which possess
the epitope recognised by the HMFG1 antibody. Lymphoproliferation has
been measured prior to antibody therapy and at fixed timepoints
thereafter. Enhanced proliferation has been demonstrated in 2/6 patients
after adjuvant intraperitoneal radioimmunotherapy and 4/10 patients
treated with multiple doses of unlabelled antibody on an idiotypic
vaccination protocol.
Treatment strategies will be outlined, methods of irnmune assessment will
be described in more detail and updated clinical and immunological results
will be presented.
079 RADIOIMMtJNOTHERAPY OF BCL-1 LYMPHOMA WITH
IODINE-131 LABELLED ANTIBODIES : DETERMINANTS OF
StICCESSFUJL THERAPY T. M. Illidge; R.Reid; and M. G. Glennie.
Lymphoma Research Laboratory, Southampton General Hospital, Southampton
S016 6YD.
The important determinants of effective radioimmunotherapy of the mouse
lymphocytic lymphoma BCL-1 have been evaluated by comparing the effects of 131-
antibodies in vivo. In contrast, to the largely disappointing results in solid tumours,
the use of radioimmunotherapy for the treatment of relapsed B cell Non-Hodgkin's
lymphomas appears to be an increasingly promising approach; with impressive
durable reported response rates. However, the mechanisms behind these encouraging
clinical responses remains largely undetermined, which has meant that the optimal
treatment approach including the relative importance of the specific target antigen
and the required dose ofradioactivity is unknown.
Here we compare antibodies against the invariant chain Ii (CD74) versus
tumour specific anti-idiotype and isotype matched control antibodies with and
without conjugated Iodine-131. Extensive biodistribution studies with lodine-125
labelled antibodies enabled accurate organ dosimetric predictions to be made before
low dose Iodine-131 (3.7-7.4 MBq) radioimmunotherapy was performed. In contrast
to recent reports in the same BCL-1 model we were able to demonstrate a very high
therapeutic efficacy (>93% cure) with 106 and 107 cells using '3'-1 anti-CD74 and no
observed toxicity. The 131-1 labelled anti-idiotype was capable of inducing very
significant increases in life-span but no cures were observed. We have demonstrated
for the first time in an animal model ofB-cell lymphoma the importance ofdelivering
radioactivity to the tumour bearing organs by the selection of an antigen target that
does not modulate significantly.
Using a range of external beam irradiation doses in the same lymphoma in
vi' ro cell line we have been able to demonstrate the exquisite radiosensitivity ofthis
lymphoma is secondary to the ability to trigger rapid and large amounts ofapoptosis
which can be modified by antibody binding. We suggest that the successful use of
RIT in the clinic is due to the ability ofthis approach to deliver systemic irradiation to
the tumour and that the radiation and antibody may induce apoptosis.